Skip to main content
eLife logoLink to eLife
. 2022 Nov 8;11:e80395. doi: 10.7554/eLife.80395

An essential periplasmic protein coordinates lipid trafficking and is required for asymmetric polar growth in mycobacteria

Kuldeepkumar R Gupta 1,, Celena M Gwin 1,, Kathryn C Rahlwes 2, Kyle J Biegas 3,4, Chunyan Wang 1,5, Jin Ho Park 1, Jun Liu 1,5, Benjamin M Swarts 3,4, Yasu S Morita 2, E Hesper Rego 1,
Editors: Christina L Stallings6, Suzanne R Pfeffer7
PMCID: PMC9678360  PMID: 36346214

Abstract

Mycobacteria, including the human pathogen Mycobacterium tuberculosis, grow by inserting new cell wall material at their poles. This process and that of division are asymmetric, producing a phenotypically heterogeneous population of cells that respond non-uniformly to stress (Aldridge et al., 2012; Rego et al., 2017). Surprisingly, deletion of a single gene – lamA – leads to more symmetry, and to a population of cells that is more uniformly killed by antibiotics (Rego et al., 2017). How does LamA create asymmetry? Here, using a combination of quantitative time-lapse imaging, bacterial genetics, and lipid profiling, we find that LamA recruits essential proteins involved in cell wall synthesis to one side of the cell – the old pole. One of these proteins, MSMEG_0317, here renamed PgfA, was of unknown function. We show that PgfA is a periplasmic protein that interacts with MmpL3, an essential transporter that flips mycolic acids in the form of trehalose monomycolate (TMM), across the plasma membrane. PgfA interacts with a TMM analog suggesting a direct role in TMM transport. Yet our data point to a broader function as well, as cells with altered PgfA levels have differences in the abundance of other lipids and are differentially reliant on those lipids for survival. Overexpression of PgfA, but not MmpL3, restores growth at the old poles in cells missing lamA. Together, our results suggest that PgfA is a key determinant of polar growth and cell envelope composition in mycobacteria, and that the LamA-mediated recruitment of this protein to one side of the cell is a required step in the establishment of cellular asymmetry.

Research organism: Other

Introduction

Mycobacterium tuberculosis, the etiological agent of human tuberculosis (TB), is responsible for approximately 1.4 million deaths each year. One of the pathogen’s distinguishing features is its unusual cell envelope. Like nearly all other bacterial species, the plasma membrane is surrounded by peptidoglycan, a rigid mesh-like structure made up of carbohydrate chains cross-linked by peptide bridges. However, in contrast to the peptidoglycan of other well-characterized bacteria, mycobacterial peptidoglycan is covalently linked to the highly branched hetero-polysaccharide arabinogalactan, which is, itself, covalently bound to extremely long-chained fatty acids called mycolic acids. Collectively, this structure is known as the mycolyl-arababinogalactan-peptidoglycan complex or mAGP. Electron microscopy has revealed that the outermost layer is a lipid bilayer, and, as such, it is referred to as the outer membrane, or, alternatively, the mycomembrane (Hoffmann et al., 2008; Zuber et al., 2008). In addition to this core structure, several lipids, lipoglycans, and glycolipids are abundantly and non-covalently interspersed across the plasma membrane and mycomembrane (Jackson, 2014; Jankute et al., 2015). This complex cell envelope is a double-edged sword: it is a formidable barrier to many antibiotics yet provides several potentially targetable structures. Indeed, two of the four first-line TB antibiotics target cell envelope biosynthesis.

In addition to their unusual cell envelope, mycobacteria differ from other well-studied rod-shaped bacteria in important ways. Notably, mycobacteria elongate by adding new material at their poles rather than along their side walls. Over the course of a cell cycle, one pole grows more than the other, giving rise to an asymmetric growth pattern (Aldridge et al., 2012). Importantly, closely related organisms like corynebacteria that have similar cell wall architecture grow more evenly from their poles, suggesting that asymmetry is not simply a consequence of polar growth and may be actively created by mycobacteria (Rego et al., 2017). In fact, while the molecular details of asymmetric polar growth are not yet well understood (Baranowski et al., 2019; Kieser and Rubin, 2014), we have discovered that LamA, a protein of unknown function specific to the mycobacterial genus, is involved (Rego et al., 2017). Deletion of lamA results in more growth from the pole formed from the previous round of division, ‘the new pole’, and less from the established growth pole, ‘the old pole’, leading to less asymmetry (Figure 1A; Rego et al., 2017).

Figure 1. PgfA is an essential polar growth factor that localizes asymmetrically.

(A) Top: Graphical depiction of growth pattern in wild type (WT) and ΔlamA cells. Green = old cell wall material. Gray = new cell wall material. Bottom: LamA is a membrane protein that co-immunoprecipitates with PonA1, a bifunctional penicillin binding protein, and MSMEG_0317/PgfA, a protein of unknown function. (B) Schematic and results of allelic exchange experiment. Vectors with pgfA or without pgfA (tetR) were transformed into a strain whose only copy of pgfA was at the L5 integration site. Transformants carrying the incoming vectors were counted by colony forming units (CFU). (C) A strain whose only copy of PgfA is tetracycline inducible was imaged over time with (+pgfA) or without (-pgfA) anhydrotetracycline (ATC). Cells were loaded into a microfluidic device 18 hr after the removal of ATC (bottom) or a mock control (top). (D) Cells whose only copy of PgfA was fused to mRFP were imaged over time by phase and fluorescence microscopy in a microfluidic device with constant perfusion of media. (E) Top: Individual cells (N=25) were followed from birth to division and the fluorescence was measured from new to old pole. Each resulting kymograph was interpolated over cell length and time and then averaged together. Using this analysis, we find that PgfA is first at the old poles (pink triangles), partially re-localizes to the septum (yellow triangles) during cell division, and then disappears from the site of division before the next cell cycle (blue triangles) to establish asymmetry in the next generation. Bottom: A depiction of this localization pattern is shown as a cartoon.

Figure 1.

Figure 1—figure supplement 1. PgfA is essential and depletion leads to reductive cell division.

Figure 1—figure supplement 1.

(A) Optical density over time of a strain whose only copy of pgfA is tetracycline inducible, with and without ATC (+/-ATC). Points are means of three biological replicates. Error bars are too small to be visible. Experiment was performed at least four times on separate days, and representative data are shown. ATC = anhydrotetracycline. Time on the x-axis corresponds to time after ATC was removed. (B) Birth lengths and cell widths over time of depletion (orange = +ATC; red = -ATC). Open circles represent individual cells (length: N=261 (length) and 253 (width) for +ATC; N=355 (length) and 254 (width) -ATC). Closed circles are not fit to the data but represent the mean of cells in 2.25 hr (length) or 2.75 hr (width) bins. The experiment was performed twice on separate days. In +ATC cultures, cell density became too high to measure length and width past ~33 hr. ATC = anhydrotetracycline (C) L5-allele swapping with pgfA or pgfA-mRFP expressed by the native promoter. Bars represent means of three biological replicates. Error bars indicate standard deviation.

Figure 1—figure supplement 2. Cells depleted of PgfA and MmpL3 do not grow from their poles.

Figure 1—figure supplement 2.

Cells from a log-phase culture were stained overnight with the fluorescent D-amino acid dye RADA at a final concentration of 2mM. The next morning, those cultures were split into two tubes, one of which received 100ng anhydrous tetracycline (aTC) to deplete either MmpL3 or PgfA. After growing for 5hr of depletion, all cells were washed of fluorescent dye, allowed to outgrow for 3hr, and imaged to visualize the amount of newly incorporated cell envelope.

Figure 1—figure supplement 3. PgfA localizes to midcell and the poles.

Figure 1—figure supplement 3.

(A) Merged phase contrast and fluorescence images of Msm cells expressing PgfA-mRFP, eGFP-Wag31, and FtsZ-mCherry2b. (B) Average fluorescent distributions over time (kymographs) from cells aligned from new to old poles and from birth to division (N=20 PgfA-mRFP; N=48 FtsZ-mCherry2B; N=20 eGFP-Wag31).

To understand LamA’s role in mycobacterial division and elongation, we identified multiple putative LamA-interacting proteins of known and unknown function (Rego et al., 2017). One of these proteins, MSMEG_0317, is predicted to be associated with several other divisome proteins (Wu et al., 2018; Figure 1A). Attempts to delete msmeg_0317 from the Mycobacterium smegmatis chromosome have been unsuccessful (Cashmore et al., 2017), and transposon insertion mapping has predicted the M. tuberculosis homolog, rv0227c, to be essential (DeJesus et al., 2017; Zhang et al., 2012). MSMEG_0317 belongs to the DUF3068-domain super-family of proteins, which are exclusively found in actinobacteria. One member of this family in corynebacteria has channel activity, so this domain has been renamed PorA (Abdali et al., 2018; Soltan Mohammadi et al., 2013). In addition, by structure-based homology prediction, MSMEG_0317 shares limited homology to CD36, which transports long-chained fatty acids into eukaryotic cells (Patel et al., 2022). In corynebacteria, the putative homolog of MSMEG_0317, LmcA, is thought to have lipid binding activity (Patel et al., 2022), and is involved in an ill-defined step of lipoglycan synthesis (Cashmore et al., 2017; Patel et al., 2022).

Here, we sought to understand the role of MSMEG_0317 in relation to LamA during mycobacterial growth and division. We find that in M. smegmatis, a model mycobacterial species, MSMEG_0317 is essential for polar growth, and localizes to the old pole in a LamA-dependent manner. There, it localizes with MmpL3, the essential mycolic acid flippase, to build the mycomembrane. Our data suggest that one function of MSMEG_0317 is to traffic mycolic acids in the periplasmic space, and that its overexpression is sufficient to restore growth at the old pole in cells missing lamA. Together, these results implicate MSMEG_0317 in mycolic acid trafficking, and argue that MSMEG_0317 is an important factor in determining cell wall composition and incorporation at one site of growth – the old pole – in mycobacteria. As such, we propose to rename MSMEG_0317, PgfA, for Polar growth factor A.

Results

PgfA is essential for polar growth and localizes to the sites of new cell wall synthesis

To verify the essentiality of pgfA in M. smegmatis, we used an allele swapping strategy (Pashley and Parish, 2003). Briefly, in a strain whose only copy of pgfA was at the L5 phage integration site (Lewis and Hatfull, 2000; van Kessel and Hatfull, 2007), we exchanged pgfA for either an empty vector or for another copy of itself (Figure 1B). Consistent with pgfA being essential for cell growth, we observed approximately 1000-fold fewer colonies when we exchanged pgfA with an empty vector compared to exchanging it for another copy of itself (Figure 1B).

To visualize the morphology of pgfA-depleted cells, we constructed a strain in which the only copy of the gene was tetracycline inducible (Figure 1C; Figure 1—figure supplement 1A). Removal of anhydrotetracycline (ATC) from the culture media prevented cell growth (Figure 1—figure supplement 1A). By time-lapse microscopy we observed that, while cells expressing PgfA became longer, on average, as cell density increased within the microfluidic device (Figure 1C; Figure 1—figure supplement 1B) cells depleted for PgfA stopped elongating but continued to divide (reductive division), became wider, and, in many instances, eventually lysed (Figure 1C, Figure 1—figure supplement 1B). As cells stopped elongating, we reasoned that PgfA is important for polar growth. To test this, we stained PgfA-depleted cells with a dye that is incorporated into peptidoglycan and monitored outgrowth in dye-free media. Consistent with the notion that PgfA is important for polar growth, we find that PgfA-depleted cells incorporate less new cell material at their poles (Figure 1—figure supplement 2).

If PgfA is important for polar growth, then it should localize to the poles. To determine where and when PgfA functions in the cell, we fused PgfA to mRFP and expressed the resulting chimera from the native pgfA promoter. By allele swapping, we find that Pnative-pgfA-mrfp restores bacterial growth (Figure 1—figure supplement 1C) and thus encodes a functional PgfA. Fluorescence microscopy at a single timepoint showed that PgfA-mRFP localizes to mid-cell and to the poles (Figure 1D, Figure 1—figure supplement 3A). In polar growing bacteria, the site of division eventually becomes the site of elongation. Thus, in addition to localizing to the poles, elongation-complex proteins can also appear at mid-cell before daughter cell separation is clearly observed. This makes it difficult to determine true septal-associated localization from a single timepoint. To disentangle whether PgfA, in addition to localizing to the poles, also localizes to the septum during division, we visualized PgfA-mRFP by time-lapse microscopy (Figure 1D). For a single cell, we measured the fluorescence distribution over time as a function of both cell cycle time and cell length. As we wanted to compare across strains, we averaged many of these individual trajectories together. The resulting ‘average’ kymograph represents the probability of finding a fluorescent protein in a particular cellular location at a particular stage of the cell cycle (Figure 1E). Using this analysis, we compared the spatiotemporal localization of PgfA-mRFP to the earliest known markers for the division complex (FtsZ-mCherry2B) and the elongation complex (eGFP-Wag31) (Figure 1—figure supplement 3B). We find that PgfA localizes primarily to the old pole before the onset of division. During division, the fluorescence intensity at the old pole becomes slightly less intense as PgfA-mRFP re-localizes to the septum (Figure 1D and E). This event occurs during the latter stages of FtsZ recruitment, but before the arrival of Wag31 to the mid-cell, suggesting that PgfA is a late divisome-associated protein (Figure 1—figure supplement 3). At the end of division, PgfA-mRFP disappears from the septal site such that the new daughter cells are once again born with an asymmetric distribution of PgfA (Figure 1D and E). Taken together, these data are consistent with PgfA being a member of both the mycobacterial division and elongation complexes and show that PgfA is essential for polar growth.

PgfA and MmpL3 are recruited to the old pole by LamA to build the mycomembrane

The manner of cell death suggested a defect in the cell envelope of PgfA-depleted cells. To resolve the layers of the mycobacterial cell envelope in detail we used cryo-electron microscopy (cryo-EM) to visualize frozen-hydrated cells. As has been previously observed (Hoffmann et al., 2008; Zuber et al., 2008), wild type M. smegmatis cells exhibit distinct plasma and outer membranes, both clearly observed as bilayers, separated by approximately 50 nm (Figure 2A). In cells depleted of PgfA, the outer membrane is frayed (Figure 2A; Figure 2—figure supplement 1) and largely devoid of electron density (Figure 2A). Thus, PgfA is important for maintaining the structural organization of mycomembrane.

Figure 2. LamA recruits PgfA and MmpL3 to the old pole to build the mycomembrane.

(A) The cell envelope of a representative wild type Msm cell and a cell depleted of PgfA for 24 hr were visualized and measured by cryo-electron microscopy. PM = plasma membrane; OM = outer membrane. Scale bar = 100 nm. (B) The lysates from strains expressing PgfA-FLAG with or without MmpL3-msfGFP were immunoprecipitated (IP) using GFP-trap beads, and the elution was probed for the presence of PgfA-FLAG via anti-FLAG Western blot. (C) Fluorescent protein fusions to either PgfA or MmpL3 were imaged by time-lapse microscopy in wild type, ΔlamA, and complement cells (ΔlamA +pNative lamA) N=25. The resulting images were then processed as described in Figure 1D. (D) The same data as panel C are plotted at a single timepoint to show the decrease in old pole accumulation of MmpL3 and PgfA in the absence of lamA. (E) Cells were depleted using CRISPRi for pgfA or mmpL3 and a representative timepoint is shown. Cell wall material is excreted from the poles and septa during depletion (white triangles).

Figure 2—source data 1. Unprocessed anti-FLAG Western blot.
Figure 2—source data 2. Unprocessed and labeled anti-FLAG Western blot.

Figure 2.

Figure 2—figure supplement 1. The cell envelopes of PgfA-depleted show outer membrane wall fraying at 24 hr (left) and 33 hr (right) of depletion.

Figure 2—figure supplement 1.

Figure 2—figure supplement 2. Full blots for the experiment in Figure 2B.

Figure 2—figure supplement 2.

The indicated strains were lysed and incubated with anti-GFP beads. The lysates (L), washes, and elution (E), were run on two separate SDS-PAGE gels, transferred, and blotted with the indicated antibodies. The bands corresponding to PgfA-3× FLAG and MmpL3-msfGFP are shown.
Figure 2—figure supplement 2—source data 1. Unprocessed anti-FLAG Western blot.
Figure 2—figure supplement 2—source data 2. Unprocessed and labeled anti-FLAG Western blot.
Figure 2—figure supplement 2—source data 3. Unprocessed and labeled anti-GFP Western blot.
Figure 2—figure supplement 2—source data 4. Unprocessed and labeled anti-GFP Western blot.
Figure 2—figure supplement 3. Kymographs of a fluorescent fusion to MurJ in wild type (WT) and in ΔlamA cells.

Figure 2—figure supplement 3.

N=25.
Figure 2—figure supplement 4. An anti-strep Western blot of wild type (WT) Msm and Msm carrying an extra copy of MSMEG_0315-strep.

Figure 2—figure supplement 4.

Figure 2—figure supplement 4—source data 1. Unprocessed anti-strep Western blot.
Figure 2—figure supplement 4—source data 2. Unprocessed and labeled anti-strep Western blot.
Figure 2—animation 1. Phase time-lapse microscopy of cells carrying anhydrotetracycline (ATC)-inducible CRISRPi guides targeting either pgfA (left) or mmpL3 (right).
Exposure to ATC occurs at the beginning of the video.

Many of the cytoplasmic and periplasmic enzymes involved in mycomembrane synthesis have been identified. However, the molecular details of how precursors are trafficked from the plasma membrane to build the complex structure are almost completely unknown. We do know that one key step involves the essential protein MmpL3, which transports trehalose monomycolate (TMM) across the plasma membrane to the periplasm (Su et al., 2021; Xu et al., 2017). There, TMM is trafficked, through unknown mechanisms, to the antigen 85 enzymes (Backus et al., 2014), and incorporated onto mAGP or made into trehalose dimycolate (TDM), a component of the outer mycomembrane leaflet (Chiaradia et al., 2017). Importantly, MmpL3 has become an anti-TB therapeutic target, as multiple compounds have been found to inhibit its function (Adams et al., 2021; La Rosa et al., 2012; Umare et al., 2021).

Using an Escherichia coli two-hybrid approach, MmpL3 from M. tuberculosis was recently found to interact with several factors involved in cell wall synthesis, growth, and division, including Rv0227c (64% identity to M. smegmatis PgfA) (Belardinelli et al., 2019). To verify that PgfA and MmpL3 interact in intact mycobacterial cells, we constructed strains that expressed fusions to these proteins to enable co-immunoprecipitation. Precipitating MmpL3-GFP with a nanobody against GFP, we found PgfA-FLAG in the elution only when MmpL3-GFP was present (Figure 2B; Figure 2—figure supplement 2). Taken together, these results show that MmpL3 and PgfA interact in the cell.

As our initial interest in PgfA was prompted by its connection to LamA, we wondered if PgfA and MmpL3 would localize differently in ΔlamA cells. Thus, we visualized fluorescent fusions to PgfA and MmpL3 in strains with and without lamA and analyzed the fluorescence distributions over time. MmpL3-msfGFP displayed the same spatial and temporal localization pattern as PgfA-mRFP, again suggesting they are part of the same complex (Figure 2C and D). Surprisingly, in ΔlamA cells, PgfA-mRFP and MmpL3-msfGFP became dramatically less abundant at the old pole, with no change in abundance at the new pole. The loss of polar PgfA and MmpL3 in ΔlamA could be complemented by integrating lamA at a single site on the chromosome (Figure 2C and D). The abundance of msfGFP-MurJ, which transports peptidoglycan precursors, was not as dramatically changed at the old pole in ΔlamA cells, showing that the LamA-dependent loss of MmpL3 and PgfA was specific and not a general loss of elongation-complex proteins (Figure 2—figure supplement 3).

If PgfA and MmpL3 are functioning together, then cells depleted of either essential protein may have the same terminal phenotype. To assay this, we created CRISPRi guides to both mmpL3 and pgfA and visualized the morphology of cells over time as the depletion was induced (Rock et al., 2017). As pgfA is predicted to be the first gene in a two gene operon (Martini et al., 2019), we were concerned about polar effects of the CRISPRi depletion (Rock et al., 2017). To address this, we integrated another copy of MSMEG_0315, the second gene in the operon, at a phage site expressed by its native promoter, and confirmed its expression by Western blot (Figure 2—figure supplement 4). Consistent with the notion that PgfA and MmpL3 function in the same pathway, we found that cells depleted for mmpL3 phenocopied those depleted for pgfA in that they become progressively shorter and wider (Figure 2—animation 1), and incorporated less material at their poles (Figure 1—figure supplement 2). By phase contrast microscopy, we also observed cell wall material excreted from the poles and the septa in both mmpL3- and pgfA-depleted cells (Figure 2E). These observations are reminiscent of cells treated with ethambutol (Wuo et al., 2022), a drug that inhibits the synthesis of arabinan, the anchor point for mycolic acids (Kilburn and Takayama, 1981; Mikusová et al., 1995). Collectively, our data are consistent with a model in which LamA recruits PgfA and MmpL3 to the old pole, either directly or indirectly, where they function to construct the mycomembrane.

PgfA is a periplasmic protein that binds TMM

A recent proteomics study identified PgfA as a putative TMM-interacting protein (Kavunja et al., 2020). To verify this, we tested whether PgfA could be captured from live M. smegmatis cells using N-x-AlkTMM-C15, a synthetic photo-cross-linkable TMM analog containing an alkyne ‘click’ chemistry handle that enables specific detection and/or enrichment of cross-linked protein interactors (Kavunja et al., 2020). M. smegmatis cells expressing PgfA-3× FLAG were incubated with N-x-AlkTMM-C15 and exposed to UV irradiation to effect cross-linking. Then, cell lysates were collected and subjected to ‘click’ reaction to dual label N-x-AlkTMM-C15-modified proteins with fluorophore and biotin affinity tags. Biotinylated proteins were captured on avidin beads, eluted, and analyzed by anti-FLAG Western blot. We found that PgfA was enriched exclusively in N-x-AlkTMM-C15-treated, UV-exposed M. smegmatis, demonstrating direct interaction between PgfA and the TMM analog (Figure 3A and Figure 3—figure supplement 1).

Figure 3. PgfA is a periplasmic protein that binds trehalose monomycolate (TMM) and is involved in TMM trafficking.

(A) Cells expressing PgfA-3× FLAG were cultured with N-x-AlkTMM-C15 (100 μM), UV-irradiated, and lysed. Lysates were reacted with azido-TAMRA-biotin reagent (AzTB) by Cu-catalyzed azide-alkyne cycloaddition (CuAAC ‘click’ reaction), and analyzed before (input) and after (output) avidin bead enrichment by anti-FLAG Western blot. The full analysis, including Coomassie and in-gel fluorescence scanning, is displayed in Figure 3—figure supplement 1. Data are representative of two independent experiments. (B) PgfA was fused to GFPmut3 at either its N- or C-terminus and integrated into Msm as the sole copy of PgfA. Cells carrying these fusions were imaged by fluorescence microscopy. Images are displayed on identical intensity scales to allow direct comparison. (C) Using CRISPRi, cells were depleted of MmpL3 or PgfA at the indicated timepoints and the cell envelopes were analyzed for TMM and trehalose dimycolate (TDM) by thin-layer chromatography (TLC). (D) Cells were induced to overexpress PgfA at the indicated timepoints, and their cell envelopes were analyzed by TLC for TMM and TDM. (E,F) Quantification of three biological replicates analyzed by TLC as shown in panels C and D. To determine statistical significance, a paired one-way ANOVA was performed that compared the intensity at the indicated timepoints to the intensity at time 0 or a no ATC control within the same replicate. *p<0.05; **p<0.005.

Figure 3—source data 1. Unprocessed MmpL3 depletion thin-layer chromatography (TLC).
Figure 3—source data 2. Unprocessed and labeled MmpL3 depletion thin-layer chromatography (TLC).
Figure 3—source data 3. Unprocessed PgfA depletion thin-layer chromatography (TLC).
Figure 3—source data 4. Unprocessed and labeled PgfA depletion thin-layer chromatography (TLC).
Figure 3—source data 5. Unprocessed PgfA overexpression thin-layer chromatography (TLC).
Figure 3—source data 6. Unprocessed and labeled PgfA overexpression thin-layer chromatography (TLC).

Figure 3.

Figure 3—figure supplement 1. Full results of experiment present in main text Figure 3A.

Figure 3—figure supplement 1.

Photoactivatable trehalose monomycolate (TMM) analog interacts with MSMEG_0317 in live Mycobacterium smegmatis. KG167 expressing 3× FLAG-tagged MSMEG_0317 was cultured with N-x-AlkTMM-C15 (100 μM), UV-irradiated, and lysed. Lysates were reacted with azido-TAMRA-biotin reagent (AzTB) by Cu-catalyzed azide-alkyne cycloaddition (CuAAC ‘click’ reaction), and analyzed before (input) and after (output) avidin bead enrichment. Input and output samples were analyzed by (A) Coomassie staining, (B) in-gel fluorescence scanning, and (C) anti-FLAG Western blot. Data are representative of two independent experiments. High-intensity band at low molecular weight in the Coomassie-stained gels represents lysozyme used in the cell lysis procedure.
Figure 3—figure supplement 1—source data 1. Unprocessed Coomassie gel.
Figure 3—figure supplement 1—source data 2. Unprocessed in-gel fluorescence scan.
Figure 3—figure supplement 1—source data 3. Unprocessed anti-FLAG Western blot.
Figure 3—figure supplement 1—source data 4. Full uncropped gels with relevant bands labeled.
Figure 3—figure supplement 2. PgfA is a transmembrane protein with two cytoplasmic tails.

Figure 3—figure supplement 2.

(A) Output from TOPCONS (https://topcons.cbr.su.se/), which aggregates the results of several transmembrane prediction algorithms. The input is MSMEG_0317, or PgfA. (B) Results of allele swapping with the indicated PgfA fusion proteins.
Figure 3—figure supplement 3. Control thin-layer chromatography (TLC) for TMM/TDM levels.

Figure 3—figure supplement 3.

Left: Wild type (WT) Msm and Msm deleted for antigen85A (MSMEG_6398) were analyzed by thin-layer chromatography (TLC). Right: Msm was treated with 20 μg/ml isoniazid for 6 hr and analyzed by TLC.
Figure 3—figure supplement 3—source data 1. Unprocessed thin-layer chromatography (TLC) comparing wild type (WT) Msm to Msm Δantigen85A.
Figure 3—figure supplement 3—source data 2. Unprocessed and labeled thin-layer chromatography (TLC) comparing wild type (WT) Msm to Msm Δantigen85A.
Figure 3—figure supplement 3—source data 3. Unprocessed thin-layer chromatography (TLC) comparing wild type (WT) Msm +/-isoniazid.
Figure 3—figure supplement 3—source data 4. Unprocessed thin-layer chromatography (TLC) and labeled comparing wild type (WT) Msm +/-isoniazid.

Several accessory proteins work with MmpL3 and/or are required to transport TMM across the plasma membrane. However, to date, all the known accessory proteins reside in the cytoplasm or have globular domains on the cytoplasmic side of the plasma membrane (Fay et al., 2019). The topology of the predicted PgfA structure shows a beta-barrel-like domain anchored by one or, possibly two, transmembrane helices (Patel et al., 2022). Prediction of the orientation with respect to the membrane is ambiguous (Figure 3—figure supplement 2A). To map the topology of PgfA, we fused mGFPmut3 to either the N- or the C-terminal side of PgfA (Figure 3B). As GFP does not fluoresce in the mycobacterial periplasm (Fay et al., 2019), we reasoned that fluorescence would indicate cytoplasmic localization of GFP. Importantly, both fusion proteins can replace wild type PgfA at high efficiency, and thus encode functional PgfA (Figure 3—figure supplement 2B). Using fluorescence microscopy, we find that the C-terminal fusion is brightly fluorescent, supporting an orientation that places the beta-barrel-like domain in the periplasmic space. Interestingly, the N-terminal fusion is significantly dimmer (Figure 3B), suggesting that further experimentation will be needed to fully understand PgfA’s interaction with the membrane. Nevertheless, collectively, these data show that PgfA is an inner membrane protein with a large periplasmic domain and that some portion of the protein binds TMM.

PgfA abundance correlates to altered TMM/TDM ratios

If PgfA is involved in the trafficking of TMM, then its depletion, as with depletion of MmpL3, should result in an altered TMM/TDM ratio (Degiacomi et al., 2017; Fay et al., 2019; Su et al., 2019; Tahlan et al., 2012). Total cell-associated amounts of TMM and TDM can be visualized by thin-layer chromatography (TLC) (Figure 3—figure supplement 3). As expected, depletion of mmpL3 leads to accumulation of TMM and a co-incident reduction of TDM (Figure 3C). To test if this is also the case for PgfA, we repeated the same procedure on cells depleted of pgfA. In this case, we find that TMM accumulates while TDM levels are more stable (Figure 3C and E). These data are consistent with a model in which TMM accumulates in a different subcellular compartment in pgfA-depleted cells, compared to mmpL3-depleted cells. Specifically, it suggests that in pgfA-depleted cells, at least some of the TMM pool may still be accessible to antigen 85 enzymes.

To further test the notion that PgfA is involved in TMM trafficking in the periplasm, we created a strain that inducibly overexpressed the protein from a multi-copy plasmid. Again, consistent with the notion that PgfA is involved in trafficking TMM, we find that inducing the overexpression of PgfA results in increased TDM levels (Figure 3D and F). Together these data support a model in which PgfA functions as part of the TMM transport pathway in the periplasm.

The abundance of PgfA negatively correlates with the abundance of lipoglycans LM/LAM

Our data indicate a role for PgfA in the transport of TMM. In contrast, the presumed corynebacterial homolog of pgfA – named lmcA – has been proposed to function in the biosynthesis of two large lipoglycans abundant in the mycobacterial cell envelope, lipomannan and lipoarabinomannan (LM/LAM) (Cashmore et al., 2017). A deletion mutant of lmcA in Corynebacterium glutamicum, resulted in disappearance of LAM and accumulation of truncated LM, which was clearly detectable by faster migration on SDS-PAGE (Cashmore et al., 2017). To test if this is also the case in mycobacteria, we used the same electrophoretic approach to analyze LM/LAM, and TLC to examine potential changes in other lipid species upon depletion of pgfA. In contrast to the results obtained in C. glutamicum, we observe a dramatic and transient increase in the total amount of cell-associated LAM during depletion, before cells began dying (Figure 4A, Figure 4—figure supplement 1). There were no obvious changes in the migration of LM/LAM on SDS-PAGE, implying that, unlike deleting lmcA in C. glutamicum, depleting PgfA in M. smegmatis minimally impacts LM/LAM biosynthesis. Additionally, other lipids, including the precursor of LM/LAM biosynthesis such as AcPIM2, show no reproducible change (Figure 4B and C; Figure 4—figure supplement 1).

Figure 4. Lipomannan and lipoarabinomannan (LM/LAM) levels negatively correlate with abundance of PgfA.

In a strain whose only copy of pgfA is anhydrotetracycline (ATC) inducible, (A) LM/LAM, (B) non-polar and polar PIMs, (C) and plasma membrane lipids were analyzed by (A) SDS-PAGE and (B–C) thin-layer chromatography (TLC) during PgfA depletion (without ATC). Cell pellets were normalized by wet weight to account for differences in cell density. To avoid changes in LM/LAM due to cell density, at the indicated timepoints, half of the cultures were taken for lipid analysis, and replaced with fresh media. Two other biological replicates are shown in Figure 4—figure supplement 1. CL, cardiolipin; PE, phosphatidylethanolamine; PI, phosphatidylinositol. (D) Results of exchanging the indicated pgfA and Corynebacterium glutamicum NCgl2760 alleles for a wild type copy of pgfA. Correct transformants are positive for the incoming selective marker and negative for the outgoing (KanR, NatS). (E) Transposon insertions in ΔlamA compared to wild type (WT). The only two genes with significantly different number of insertions (reduced) were lamA itself and sucT, a gene that codes for a protein known to modify LAM and arabinogalactan. (F) In WT cells and those carrying an ATC-inducible copy of pgfA on a multi-copy plasmid, cell-associated LM/LAM were extracted, separated via SDS-PAGE, and visualized by ProQ Emerald with and without ATC at the indicated timepoints.

Figure 4—source data 1. Unprocessed lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA depletion.
Figure 4—source data 2. Unprocessed PIM thin-layer chromatography (TLC) during PgfA depletion.
Figure 4—source data 3. Unprocessed plasma membrane thin-layer chromatography (TLC) during PgfA depletion.
Figure 4—source data 4. Unprocessed, lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE, PIM, and plasma membrane thin-layer chromatography (TLC) during PgfA depletion, with relevant bands labeled.
Figure 4—source data 5. Results of Tn-seq experiment comparing insertions in wild type and ΔlamA.
elife-80395-fig4-data5.xlsx (578.1KB, xlsx)
Figure 4—source data 6. Unprocessed lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA overexpression.
Figure 4—source data 7. Unprocessed and labeled lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA overexpression.

Figure 4.

Figure 4—figure supplement 1. Two additional biological replicates of lipomannan and lipoarabinomannan (LM/LAM) analysis during PgfA depletion.

Figure 4—figure supplement 1.

(A) As in main text Figure 4A, LM/LAM and other lipids were extracted and separated by SDS-PAGE and thin-layer chromatography (TLC) in cells expressing (+ATC) and depleted for (-ATC) PgfA. Two biological replicates are shown. (B) For the same replicates optical density was measured during depletion. To avoid changes in LM/LAM due to cell density, at the indicated timepoints, half of the cultures were taken for lipid analysis and replaced with fresh media.
Figure 4—figure supplement 1—source data 1. Unprocessed lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA overexpression.
Figure 4—figure supplement 1—source data 2. Unprocessed PIM thin-layer chromatography (TLC) during PgfA overexpression, left-hand side.
Figure 4—figure supplement 1—source data 3. Unprocessed PIM thin-layer chromatography (TLC) during PgfA overexpression, right-hand side.
Figure 4—figure supplement 1—source data 4. Unprocessed plasma membrane thin-layer chromatography (TLC) during PgfA overexpression, left-hand side.
Figure 4—figure supplement 1—source data 5. Unprocessed plasma membrane thin-layer chromatography (TLC) during PgfA overexpression, right-hand side.
Figure 4—figure supplement 1—source data 6. Full uncropped gels with relevant bands labeled.
Figure 4—figure supplement 2. Corynebacterial LmcA cannot functionally replace PgfA in mycobacteria.

Figure 4—figure supplement 2.

(A) Results of exchanging the indicated pgfA alleles for a wild type copy of pgfA. Bars represent medians. (B) Cell morphology analysis of a surviving transformant. Lines represent medians. (C) Results of exchanging the indicated pgfA alleles for a wild type copy of pgfA. Bars represent medians.

These data led us to hypothesize that PgfA and LmcA do not have the same function, even though there is synteny in their chromosomal location. Indeed, PgfA and LmcA share only 21% sequence identity and there are marked differences in their structures (Patel et al., 2022), most noticeably a long C-terminal cytoplasmic tail that is critical to the function of PgfA but missing in LmcA (Figure 4D; Figure 4—figure supplement 2A–B). Thus, we wondered if LmcA can substitute for PgfA in M. smegmatis. To test this, we used our allele swapping strategy. We found that lmcA, even with PgfA’s cytoplasmic tail, is unable to substitute for pgfA in M. smegmatis (Figure 4D; Figure 4—figure supplement 2C). Thus, while both pgfA and lmcA mutants have altered LM/LAM profiles, collectively, our data suggest that further studies are needed to confirm if they are true orthologs.

Why does depletion of PgfA result in an accumulation of LM/LAM? To investigate this, we decided to leverage ΔlamA cells, which naturally have less PgfA and MmpL3 (Figure 2C). PgfA and MmpL3 have been described as highly vulnerable drug targets, that is, a small change in their abundance causes growth arrest or cell death (Bosch et al., 2021). How do ΔlamA cells grow at a normal rate with fewer of these essential proteins? We reasoned that changes in gene essentiality in ΔlamA may uncover compensatory mechanisms that promote survival. Thus, we created transposon libraries in ΔlamA and wild type cells and compared insertions across the genomes. There were very few changes: aside from ΔlamA itself, the only gene that sustained significantly fewer insertions in ΔlamA across replicates was MSMEG_3187 or sucT (Figure 4E; Figure 4—source data 1). SucT succinylates arabinogalactan and LAM, a modification that changes the structural properties of the mycomembrane (Palčeková et al., 2019). These data suggest that in cells deleted for lamA, in which the levels of PgfA and MmpL3 are lower, the presence of lipoglycans or their modifications become more important. In fact, we find that cells overexpressing PgfA, which results in more TDM (Figure 3D and F), also have lower levels of cell-associated LAM (Figure 4F).

Taken together, our data suggest that PgfA is important for maintaining the correct levels of LM/LAM in the cell envelope. Further, our data uncover a previously unknown connection between TMM transport, or assembly of the mycomembrane, and LM/LAM. We find that the levels of LAM, and to a lesser extent LM, are negatively correlated with the levels of PgfA-mediated TMM trafficking, suggesting that there may be competing pathways for the transport or synthesis of these molecules, a notion supported genetically by Tn-seq. Alternatively, altered PgfA-mediated TMM trafficking may lead to differences in LM/LAM accessibility to extraction methods.

PgfA is necessary and sufficient for old pole growth in ΔlamA and the molecular requirements for growth between the poles are different

We have shown that PgfA and MmpL3 are necessary for polar growth (Figure 1C–E; Figure 1—figure supplement 2). Additionally, in ΔlamA cells, which grow less from the old pole, PgfA and MmpL3 are less abundant at this site (Figure 2C–D). We wondered if loss of old pole growth in ΔlamA cells could be directly attributed to the lowered abundance of either PgfA or MmpL3 at this site. To test if PgfA and/or MmpL3 are sufficient to restore old pole growth in ΔlamA, we created strains that expressed a second copy of these genes driven by a strong ribosomal promoter. These strains had no discernible differences in growth rate, with similar timing between successive division events of individual cells (Figure 5—figure supplement 1). By quantifying polar growth with an established pulse chase assay (Aldridge et al., 2012; Rego et al., 2017), we find that ΔlamA cells encoding an extra copy of pgfA, but not mmpL3, grow more from the old pole over the course of the cell cycle (Figure 5A). These data suggest that the function of PgfA or its interaction with other factors is necessary and sufficient for growth from the old pole in M. smegmatis.

Figure 5. PgfA is sufficient to restore old pole growth in ΔlamA cells.

(A) Cells were stained with amine-reactive dye, loaded into a microfluidic device, and imaged while perfusing dye-free media. By following the amount of unlabeled cell wall material, growth at the old and new poles was measured over time. The amount of growth incorporated per cell cycle is compared across wild type (WT) cells, ΔlamA cells, and ΔlamA cells expressing a second copy of pgfA or mmpL3 driven by a strong promoter. To determine statistical significance, this procedure was repeated three times on separate days with independently grown cultures (N=3) (colors represent the replicates). For each replicate, a median was calculated (solid circles). A paired one-way ANOVA was performed comparing the medians of the replicates (aka a ‘super plot’). All strains were compared against ΔlamA. Solid lines represent the means of the solid circles. *p<0.05; **p<0.005. (B) Cells were stained with a fluorescent D-alanine analog, HADA, fixed, and imaged by fluorescence microscopy. MicrobeJ was used to segment the cells and measure intensity profiles along the long axis of the cell. Profiles were then aligned by the brightest pole and ordered by length as a proxy for cell cycle. (N=194 WT; N=259 ΔlamA; N=335 ΔlamA +lamA) (C) A model for asymmetric growth. PgfA is recruited by LamA to the old pole, where, together with other proteins, it functions to organize the mycobacterial cell envelope and promote fast cell elongation at one side of the cell.

Figure 5.

Figure 5—figure supplement 1. The inter-division time (the time between birth and division) was compared across strains and replicates as described in Figure 5A.

Figure 5—figure supplement 1.

Significance was calculated using a one-way paired ANOVA as described in Figure 5A.

Intriguingly, overexpression of PgfA does not lead to more growth at the new pole (Figure 5A). This mirrors the observation that in ΔlamA cells – which grow more from the new pole – neither MmpL3 nor PgfA are more abundant at this pole (Figure 2C). Instead, the levels of msfGFP-MurJ become increased (Figure 2—figure supplement 3), leading us to hypothesize that peptidoglycan synthesis increases at this site in the absence of lamA. To test this, we stained cells with the fluorescent D-Ala analog HADA, which is incorporated into peptidoglycan through the cytoplasmic route of synthesis (García-Heredia et al., 2018). In agreement with the increased MurJ abundance at the new pole, we find that ΔlamA cells have increased HADA staining at the new pole (Figure 5B). These data suggest that the molecular requirements for growth between the new and old poles may be different: with PgfA being rate limiting at the old pole and PG synthesis being rate limiting at the new pole.

Discussion

Our understanding of the mechanisms that govern polar growth and division are at a nascent stage compared to our understanding of these processes in model rod-shaped bacteria (Baranowski et al., 2019; Kieser and Rubin, 2014). This is unfortunate because the enzymes that create and remodel the cell envelope are a rich source of anti-bacterial drug targets. In addition, the unusual mode of asymmetric polar growth – coupled with the complexity of constructing the multi-layered mycobacterial cell envelope – means that the details of growth and division in mycobacteria are almost certainly different from laterally growing rod-shaped bacteria.

Here, we investigate the function of a mycobacterial specific factor LamA. We had previously shown that LamA is, in part, responsible for asymmetric polar growth. Cells missing lamA grow more symmetrically and are uniformly susceptible to several drugs (Rego et al., 2017). How does LamA create asymmetry? We make inroads into answering this question by investigating the cellular function of MSMEG_0317, another protein of unknown function, which was predicted to interact with LamA. We show that MSMEG_0317, renamed PgfA, is involved in the trafficking of mycolic acids in the periplasmic space. In fact, it is unknown how TMMs are physically placed in the mycomembrane. It has been hypothesized that MmpL3 must hand off TMMs to another protein or proteins in the periplasm before they can be incorporated into mAGP or made into TDM by antigen 85 enzymes (Adams et al., 2021). We find that PgfA interacts with both MmpL3 and TMM, and that cells depleted for PgfA display phenotypes consistent with PgfA filling some intermediate role between MmpL3 and subsequent placement of mycolic acids in the mycomembrane. Further research will be needed to precisely establish PgfA’s role in TMM transport; nevertheless, these results advance our understanding of how the mycomembrane is constructed.

In addition to its role in TMM transport, our data point to a more global function for PgfA in determining the composition of the cell envelope. Specifically, we find that PgfA levels negatively correlate with the abundance of LAM, and to some extent LM, two large and abundant lipoglycans in the cell envelope (Figure 4). These data suggest that there may be compensatory or competing mechanisms for the transport and/or synthesis of TMM and LM/LAM (Figure 5C). Further strengthening that argument, we find that ΔlamA cells, which have less PgfA, are more reliant on SucT – an enzyme that succinylates LAM and arabinogalactan (Bhamidi et al., 2008; Palčeková et al., 2019). It may be that TMM and LM/LAM are simply competing for space in the outer leaflet of the mycomembrane. However, to date, altered LM/LAM levels have not been reported for other TMM-trafficking mutants, suggesting that there may be more active regulation controlling the levels or transport of these two molecules. Indeed, others have speculated that succinylation itself may act to negatively regulate mycoloylation, as succinylated arabinan chains are found to be unmycoloylated (Bhamidi et al., 2008). Deletion of lamA results in less PgfA and MmpL3 at one side of the cell, the ‘old pole’, leading to less growth from that side of the cell. Increased expression of PgfA but not MmpL3 restores growth at that side of the cell, suggesting that PgfA’s role in coordinating lipid trafficking, or the presence of the protein itself, is rate limiting for growth at the old pole (Figure 5C). Further research will be needed to understand how a TMM-binding protein influences the rate of cell wall insertion at the old pole. Indeed, insertion of new cell wall material requires the concerted effort of many synthetic enzymes, including those that polymerize and cross-link peptidoglycan. In mycobacteria, the bifunctional class A PBPs (aPBPs) are the dominant enzymes required for cell elongation. In other organisms, aPBPs are activated by inner or outer membrane-anchored proteins (Fenton et al., 2018; Paradis-Bleau et al., 2010; Typas et al., 2010), though no activator of PonA1 – the major aPBP in mycobacteria – has been found. Thus, it is intriguing to speculate that mycomembrane precursor transport may play a role in activating PG synthesis at the old pole in mycobacteria. What are the requirements for growth at the new pole – the pole newly formed by division? In ΔlamA, this pole grows more without an increase in PgfA or MmpL3 (Figure 2C); instead, enzymes involved in PG synthesis are more abundant at this site in ΔlamA. These observations suggest that the requirements for growth between the two poles are fundamentally different, at least for a certain time after the onset of pole elongation. Indeed, new poles will eventually become old poles in the next round of division. We see that PgfA and MmpL3 localize to the ‘new old poles’ after division, establishing asymmetry in the next generation. How does LamA affect the growth of the poles in opposite directions – inhibiting one but activating another? Future research is needed, but our data suggest that the new and old poles of mycobacteria may be distinct sites, with different molecular factors and requirements for growth. Our results suggest that LamA influences these differences to create asymmetry in individual cells, leading to a heterogeneous population better able to survive certain stresses, like antibiotics.

Materials and methods

Key resources table.

Reagent type (species) or resource Designation Source or reference Identifiers Additional information
Strain, strain background (Mycobacterium smegmatis) Mycobacterium smegmatis mc2155 Wild type Mycobacterium smegmatis
Strain, strain background (Mycobacterium smegmatis) KG26 This work mc2155 ∆MSMEG_0317 L5::pTetO-MSMEG_0317 Parental swap strain
Strain, strain background (Mycobacterium smegmatis) HR342 Rego et al., 2017 mc2155 ∆MSMEG_4265 LamA knockout strain
Strain, strain background (Mycobacterium smegmatis) KG97 This work mc2155 ∆MSMEG_0317 L5::pTetO-MSMEG_0317-myc / pTetR Strain used for the
anhydrotetracyline-inducible depletion of PgfA
Strain, strain background (Mycobacterium smegmatis) KG81 This work mc2155 ∆MSMEG_0317 pL5::pNative-MSMEG_0317 -mRFP-myc Strain used for determining PgfA localization
Strain, strain background (Mycobacterium smegmatis) HR388 Rego et al., 2017 mc2155 L5::pG-MCK-ptb21-eGFP-wag31 tweety::ptb21-ftsZ-mCherry2B Strain used to determine localization of FtsZ and Wag31
Strain, strain background (Mycobacterium smegmatis) CMG184 This work mc2155 tw::ptb21 mmpL3TB-msfGFP Strain used to determine localization of MmpL3
Strain, strain background (Mycobacterium smegmatis) CMG530 This work mc2155 ∆MSMEG_0317 L5::pTetO-MSMEG_0317-3x- FLAG tw::ptb21-mmpL3TB-msfGFP Strain used for co-immunoprecipitation of MmpL3 and PgfA
Strain, strain background (Mycobacterium smegmatis) KG167 This work mc2155 ∆MSMEG_0317 L5::pTetO-MSMEG_0317-3x-FLAG Control strain used for co-immunoprecipitation of MmpL3 and PgfA
Strain, strain background (Mycobacterium smegmatis) CMG184 This work mc2155 tw::ptb21-mmpL3TB-msfGFP Strain used to determine localization of MmpL3
Strain, strain background (Mycobacterium smegmatis) CMG481 This work mc2155 ∆lamA::zeo L5:: pNative-lamA-strep tw:: ptb21-mmpL3TB-msfGFP Strain used to determine localization of MmpL3 in a ∆lamA background with LamA complemented under its native promoter
Strain, strain background (Mycobacterium smegmatis) CMG557 This work mc2155 L5::pTetO-MSMEG_0317-myc Strain used for measuring polar growth in a PgfA merodiploid background
Strain, strain background (M. smegmatis) KG175 This work mc2155 ∆lamA L5::pTetO- MSMEG_0317-myc Strain used for measuring polar growth in a PgfA merodiploid and LamA knockout background
Strain, strain background (Mycobacterium smegmatis) CMG585 This work mc2155 L5::pTetO-mmpL3TB-myc Strain used for measuring polar growth in an MmpL3 merodiploid background
Strain, strain background (Mycobacterium smegmatis) CMG587 This work mc2155 ∆lamA L5:: pTetO-mmpL3TB-myc Strain used for measuring polar growth in an MmpL3 merodiploid and LamA knockout background
Strain, strain background (Mycobacterium smegmatis) KG154 This work mc2155 ∆lamA ∆MSMEG_0317 L5::pNative-MSMEG_0317 -mRFP-myc Strain used for PgfA localization in LamA knockout background
Strain, strain background (Mycobacterium smegmatis) KG157 This work mc2155 ∆lamA ∆MSMEG_0317 L5::pNative-MSMEG_0317 -mRFP-myc L5::pNative-lamA-strep Strain used for PgfA localization in a background where lamA was complemented in LamA knockout
Strain, strain background (Mycobacterium smegmatis) CMG206 This work mc2155 tw::ptb21-msfGFP-MurJTB Strain used for localization of MurJ
Strain (Mycobacterium smegmatis) CMG199 This work mc2155 ∆lamA tw::ptb21-msfGFP-murJTB Strain used for localization of MurJ in a LamA knockout background
Strain, strain background (Mycobacterium smegmatis) CMG485 This work mc2155 ∆lamA::zeo L5::pNative-LamA-strep tw::ptb21-msfGFP-MurJTB
Strain used for localization of MurJ in a LamA knockout background where LamA was complemented under its native promoter
Strain, strain background (Mycobacterium smegmatis) KG244 This work mc2155 L5::pLJR962-mmpL3-sgRNA CRISPR-inducible MmpL3 depletion strain
Strain, strain background (Mycobacterium smegmatis) KG289/
CMG549
This work mc2155 L5::pLJR962- MSMEG_0317-sgRNA tw::pNative- MSMEG_0315-strep CRISPR-inducible PgfA depletion strain
Strain, strain background (Mycobacterium smegmatis) KG47 This work mc2155 ∆MSMEG_0317 L5::pTetO-MSMEG_0317-mGFPmut3-myc C-terminal GFP tagged PgfA strain
Strain, strain background (Mycobacterium smegmatis) KG73 This work mc2155 ∆MSMEG_0317 L5::pTetO-mGFP-mut3- MSMEG_0317-myc N-terminal GFP tagged PgfA strain
Strain, strain background (Mycobacterium smegmatis) KG167 This work mc2155 ∆MSMEG_0317 L5::pTetO- MSMEG_0317-3xFLAG Strain carrying MSMEG_0317-3×-FLAG, used for TMM pulldown
Strain, strain background (Mycobacterium smegmatis) KG60 This work mc2155 /pTetOR- MSMEG_0317-myc Strain carrying tetracycline inducible overexpression plasmid for PgfA
Strain, strain background (Mycobacterium smegmatis) KG286 This work mc2155 Δmsmeg_0317 L5::pTetO- MSMEG_0317-ΔC Strain carrying msmeg_0317 without c-terminal cytoplasmic tail
Strain, strain background (Mycobacterium smegmatis) HR404 This work mc2155 ΔMSMEG_6398 Antigen 85A KO strain used in TLC control experiments
Recombinant DNA reagent KG147 (plasmid) This work DH5α
/ pL5-pTetO-Ncgl2760-myc
Plasmid carrying corynebacterial ncgl2760 gene
Recombinant DNA reagent KG284 (plasmid) This work DH5α
/ pL5-pTetO-Ncgl2760-MSMEG_0317-C-term
Plasmid carrying corynebacterial ncgl2760 gene fused to cytosolic C-terminal of msmeg_0317 gene
Recombinant DNA reagent CMG541 (plasmid) This work Dh5a / pTweety-pNative MSMEG_0315-strep Plasmid carrying mycobacterial gene MSMEG_0315 with a C-terminal strep tag

Bacterial strains and culture conditions

M. smegmatis mc2155 was grown in Middlebrook 7H9 broth supplemented with 0.05% Tween80, 0.2% glycerol, 5 gm/l albumin, 2 gm/l dextrose, and 0.003 gm/l catalase or plated on LB agar. E. coli DH5α cells were grown in LB broth or on LB agar plates. Concentrations of antibiotics used for M. smegmatis is as follows: 20 μg/ml zeocin, 25 μg/ml kanamycin, 50 μg/ml hygromycin, and 20 μg/ml nourseothricin. Concentrations of antibiotics used for E. coli used for E. coli are as follows: 40 μg/ml zeocin, 50 μg/ml kanamycin, 100 μg/ml hygromycin, and 40 μg/ml nourseothricin.

Plasmid and strain construction

Strains used in this study are listed in Key resources table. Oligos and primers are listed in Supplementary file 1. In brief, before deleting the native copy of MSMEG_0317 (pgfA), a merodiploid strain was created by inserting a second copy of MSMEG_0317 gene under pTetO promoter using a KanR L5 integrating vector. Subsequently, in the merodiploid strain, an in-frame deletion was made by replacing the native copy of MSMEG_0317 gene with a zeocin resistance cassette flanked by loxP sites using recombineering (van Kessel and Hatfull, 2007). MSMEG_0317 and its variants, including the fluorescent protein fusions, were cloned in a NatR L5 integrating vector for allele exchange at the L5 site. The MSMEG_0317 depletion strain was made by transforming an episomal HygR marked vector constitutively expressing TetR repressor into a strain expressing a single copy of MSMEG_0317 controlled by the pTetO promoter. For expression of MSMEG_0317 driven by the native promoter, 200 bp upstream of MSMEG_0317 chromosomal locus was used. For the MmpL3 and MurJ fluorescent fusions and co-immunoprecipitation experiments, the genes were cloned from the M. tuberculosis genome, expressed from the ptb21 promoter and integrated in single copy at the tweety phage integration site. All plasmid constructs were made using isothermal Gibson assembly whereby insert and vector backbone shared 20–25 bp of homology.

MSMEG_0317 depletion

Promoter depletion

To transcriptionally deplete MSMEG_0317 in Msm, the ATC-inducible Tet-ON system was used. The only copy of MSMEG_0317 was driven by the pTetO promoter, while the TetR repressor was constitutively expressed in trans from an episomal vector. MSMEG_0317 was depleted by removing ATC from the medium and cells were grown for 18 hr. Subsequently, MSMEG_0317-depleted cells were re-diluted in fresh medium, also without ATC, and samples at different timepoints were taken and processed for cryo-EM. Alternatively, to avoid changes in LM/LAM abundance that have been found to be correlated with cell density and growth phase (21), at 18 hr of depletion, half of the culture was removed for lipid extraction and analysis, and replaced with fresh media. Lipid analysis was performed at timepoints before and after the decrease in OD indicating cessation of growth (Figure 4—figure supplement 1).

CRISPRi depletion

To transcriptionally deplete MmpL3 and MSMEG_0317 using CRISPRi, both dCas9 and the respective guide RNAs were cloned in an L5 integrating plasmid plJR962 (Rock et al., 2017). The CRISPRi silencing of mmpL3/MSMEG_0317 was induced by adding ATC to a final concentration of 100 ng/µl. The induction was carried out for the indicated timepoints.

Time-lapse and fluorescence microscopy

An inverted Nikon Ti-E microscope was used for the time-lapse and snapshot imaging. An environmental chamber (Okolabs) maintained the sample at 37°C. To reduce phototoxicity exposure times were kept below 100 ms for excitation with 470 nm and 300 ms for excitation with 550 nm.

Time lapse

Exponentially growing cells were cultivated in an B04 microfluidics plate from CellAsic, continuously supplied with fresh 7H9 medium, and imaged every 15 min using a 60× 1.4 NA Plan Apochromat phase contrast objective (Nikon). Fluorescence was excited using the Spectra X Light Engine (Lumencor), separated using single- or multi-wavelength dichroic mirrors, filtered through single bandpass emission filters, and detected with an sCMOS camera (ORCA Flash 4.0). Filters are: GFP (Ex: 470/24; Em: 515/30 or 525/50); mRFP (Ex: 550/15; Em: 595/44 or 630/75).

RADA pulse chase

To generate the data shown in Figure 2—figure supplement 1, cells from a log-phase culture were stained overnight with the fluorescent D-amino acid dye RADA at a final concentration of 2 mM. The next morning, those cultures were split into two tubes, one of which received 100 ng anhydrous tetracycline (aTC) to deplete either MmpL3 or PgfA; the other tube did not receive aTC as a control. After growing for 5 hr of depletion, all cells were washed of fluorescent dye by centrifugation and resuspension in growth media, and allowed to outgrow another 3 hr. All samples were then imaged under 1% agarose Hartmans-de Bont (HdB) pads. RADA dye was captured by using a custom TRITC filter system (Ex: 560/40 or 550/10; Em: 630/73) with an excitation time of 50 ms.

Kymograph analysis and image analysis

Time-lapse images were analyzed in open-source image analysis software Fiji (30) and a custom MATLAB program was used to generate kymographs. Source code will be uploaded to GitHub. Specifically, for a single cell, in Fiji, a 5-pixel wide segmented line was drawn from the new pole to the old pole at each timepoint during the cell cycle. This was repeated on 20–50 cells. These line profiles were then imported into MATLAB, where a custom script was used to generate an average kymograph by 2D interpolation of the individual kymographs. For the demographs shown in Figure 5, cells were segmented and intensity profiles measured using MicrobeJ. Output intensity profiles were then transferred to MATLAB, sorted by cell length, and aligned by the brightest pole for visualization. For pulse chase assays shown in Figure 5, cells were measured using a 7-pixel wide segmented line drawn from the new pole to the old pole at two points during the cell cycle: birth and the frame before division. These line profiles were then imported into MATLAB, where a custom script was used to measure the amount of growth at each pole during a single generation.

N-x-AlkTMM-C15-mediated protein capture

Preparation of cell lysate

M. smegmatis expressing 3× FLAG-tagged MSMEG_0317 starter culture was generated by inoculating a single colony from a freshly streaked LB agar plate supplemented with zeocin and nourseothricin (20 µg/ml each) into 10 ml liquid 7H9 medium in a sterile culture tube. The starter culture was grown until mid-logarithmic phase and then diluted to OD600 0.2 with 7H9 medium to a final volume of 80 ml. The culture was split into two equal volumes in 125 ml sterilized culture flasks. To one flask, N-x-AlkTMM-C15 was added to a final concentration of 100 μM with (final DMSO concentration of 2%), while the other flask was left untreated as a DMSO control (final DMSO concentration of 2%). Both flasks were incubated with shaking until OD600 0.8 was reached. The cells were pelleted by centrifugation at 6500× g at 4°C for 10 min. The cell pellets were washed twice with PBS, resuspended in 6 ml PBS, and split into two equal volumes. One aliquot was exposed to UV irradiation for 30 min with a 5 W 365 nm UV bench lamp (UVP) while the other was left unexposed as a control. The cell pellets were collected by centrifugation and resuspended in 600 μl lysis buffer (2 mg/ml lysozyme, 1 mM phenylmethylsulfonyl fluoride in 1× PBS), transferred to scintillation vials, and incubated at 37°C for 2 hr. The mixtures were transferred to 1.5 ml screw-cap vials containing 0.25 ml of 0.1 mm zirconia/silica beads (BioSpec Products) and subjected to bead beating 3× for 1 min each using a FastPrep-24 bead beater (MP Biomedicals). The lysate was transferred to a scintillation vial, then SDS was added to a final concentration of 2% from a 20% SDS stock. Cell extracts were incubated at 60°C for 2 hr with constant stirring. The lysates were transferred to microcentrifuge tubes and centrifuged at 3200× g for 10 min at 4°C. The supernatant was collected and stored in separate tubes at 4°C until use.

CuAAC and affinity enrichment

To reduce SDS concentration, 500 μl of methanol/chloroform (2:1 v/v) was added to 184 μl of cell lysate. The resulting protein precipitate was centrifuged at 18,000× g at 4°C for 10 min and the supernatant was discarded. The precipitate was air-dried and solubilized using 184 μl of 0.5% SDS/0.05% LDAO buffer. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) was carried out by sequential addition of 1 mM AzTB (azido-TAMRA-biotin (4 μl), Click Chemistry Tools), 60 mM sodium ascorbate (4 μl), 6.4 mM TBTA ligand (4 μl), and 50 mM copper sulfate (4 μl) to give a final volume of 200 μl. The final reagent concentration was 20 μM AzTB; 1.2 mM sodium ascorbate; 128 μM TBTA; and 1 mM copper(II) sulfate. The mixture was thoroughly mixed by pipetting up and down and the reaction was incubated for 2 hr in the dark with constant agitation at 37°C. Excess AzTB was removed by precipitating proteins in methanol/chloroform (2:1 v/v), discarding supernatant, and solubilizing protein pellets in 200 μl 0.5% SDS/0.05% LDAO buffer as described above. Protein concentration was determined by Bradford assay. Fifteen μl of each sample was saved as input sample. The remaining sample was mixed with 40 μl Pierce avidin-agarose beads (Thermo Fisher Scientific) that had been pre-washed 3× with 0.5% SDS/0.05% LDAO buffer (100 μl). The bead mixture was incubated at room temperature with constant rotation for 2 hr. The beads were washed 3× with 0.5% SDS/0.05% LDAO buffer (100 μl) followed by 3× with PBS (100 μl) with centrifugation at 1000× g for 1 min between each wash. Bound proteins were eluted by boiling at 95°C for 15 min in 30 μl of 4× sample buffer.

SDS-PAGE and Western blot

Five μg of input and 10 μl of output was resolved by SDS-PAGE by 4–20% acrylamide gels and analyzed by in-gel fluorescence using a Typhoon FLA 7000 (GE Healthcare Life Science) using the rhodamine channel to detect TAMRA-labeled proteins.

The gel was fixed for 15 min (40% ethanol and 10% acetic acid in DI water), rinsed 3× with DI water 10 min each and stained overnight with agitation in QC colloidal Coomassie stain (Bio-Rad). The gel was rinsed with DI water 3× for 10 min and imaged using a ChemiDoc Touch Imaging System (Bio-Rad) and processed by Image Lab software (Bio-Rad).

The above conditions were used to generate samples for Western blot analysis. Five μg input controls and 10 μl eluted proteins were resolved by SDS-PAGE. After gel electrophoresis, proteins were transferred onto an Immun-Blot PVDF membrane (Bio-Rad). The PVDF membrane was equilibrated in ethanol and blotting filter paper (Thermo Fisher Scientific) was equilibrated in transfer buffer (25 mM Tris, 193 mM glycine, and 20% ethanol) before placement in a transfer cassette. Proteins were transferred electrophoretically at a constant voltage of 25 V for 7 min using a Trans-Blot Turbo Transfer System (Bio-Rad). After transfer, the membrane was blocked overnight at 4°C in 5% dry milk in Tris-buffered saline containing Tween 20, pH 7.6 (50 mM Tris, 0.5 M NaCl, 0.02% Tween 20 [TBST]). Anti-FLAG-HRP (Thermo Fisher Scientific) was used at 1:1000 dilution using 2% dry milk in TBST. The membrane was incubated with antibody at 4°C overnight with constant rocking. The membrane was washed 3× for 10 min each with TBST. The membrane was treated with SuperSignal West Pico PLUS chemiluminescent reagent (Thermo Fisher Scientific) and chemiluminescence was detected on a ChemiDoc Touch Imaging system (Bio-Rad).

Tn-seq

Transposon libraries in wild type and ΔlamA (HR342) were prepared as and sequenced described elsewhere (Dragset et al., 2019). This was done independently on two separate days for a total of two biological replicates in each strain. The TRANSIT and TPP python packages were used to map insertions to the mc2155 genome and quantitatively compare insertions across stains, using the ‘resampling’ option (DeJesus et al., 2015).

Co-immunoprecipitation

Sample preparation and immunoprecipitation

Mycobacterial cultures were grown to mid-log phase as described above. Protocol for cross-linking was adapted from Belardinelli et al., 2019. Cells were washed with 1× phosphate buffered saline (PBS) once. Pellets were resuspended in 1 ml of 1× PBS with 1.25 mM dithiobis(succinimidyl propionate) and incubated for 30 min at 37°C for cross-linking. After incubation, cells were pelleted at 10,000× g for 5 min at room temperature and the supernatant was discarded. The pellet was resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 10 ug/ml DNase I; one tablet Roche cOmplete EDTA free protease inhibitor cocktail; and 0.5% Igepal Nonidet P40 Substitute) and lysed with a BeadBug Microtube Homogenizer at 4000 rpm six times for 30 s each, icing in between. Lysed cells were spun down at 15,000× g for 15 min at 4°C, and the supernatant was transferred to a clean Eppendorf tube. Lysates were incubated, where indicated, with either GFP-Trap Magnetic Agarose (Chromotek) or magnetic a-FLAG M2 beads (Sigma-Aldrich) and incubated at 4°C overnight, rotating. After incubation, samples were spun down at 2500× g for 1 min at room temperature and flow through was discarded. Beads were washed three times with non-detergent wash buffer (10 mM Tris-HCl, pH 7.4; 150 mM NaCl, 0.5 mM EDTA). GFP-Trap samples were eluted with 2× Laemmli Buffer (Bio-Rad) prepared with 50 mM (DTT) and boiled at 95°C for 5 min. FLAG M2 beads were eluted twice with 3× FLAG peptide (Sigma-Aldrich) for 30 min rotating at 4°C. All samples not already treated with Laemmli Buffer + DTT were prepared for Western blotting by addition of Laemmli Buffer + DTT and boiled at 95°C for 5 min, to reverse all cross-links.

Western blot verification

Samples were run on NuPAGE (Thermo Fisher) 4–12% Bis-Tris gels in 1× MOPS-SDS running buffer. Proteins were transferred to nitrocellulose membranes and probed with 1:1000 a-FLAG primary (Sigma-Aldrich, clone M2) and 1:5000 a-mouse secondary (Thermo Fisher, Superclonal A28177). SuperSignal West Femto Extended Duration Substrate (Thermo Fisher) was used for chemiluminescent visualization on an Amersham ImageQuant 800 system.

Lipid extraction and analysis

TMM/TDM

Crude lipids were extracted from equal wet cell pellet weights of the either mmpL3 depletion or MSMEG_0317-depleted cells after 9, 12, and 15 hr with or without ATC with 2:1 chloroform/methanol mixture for 12 hr. The organic layer was separated from the cell debris centrifugation at 4000× g. The organic extract was air-dried overnight. The dried extract was dissolved in 50 μl of 2:1 chloroform/methanol. TMMs and TDMs were separated on by high-performance thin layer chromatography (HPTLC) (Silica gel 60, EMD Merck) using chloroform/methanol/water (25:4:9:0.4). TMMs/TDMs were visualized by spraying the TLC sheet with 20% 1-napthaol in 5% sulfuric acid and charring the plate at 110°C Trehalose containing lipids (TMMs/TDMs) appear as purple bands after charring.

LM/LAM

Extraction, purification, and analysis of lipids were as described previously (Rahlwes et al., 2019). Briefly, crude lipids were extracted from equal wet cell pellet weights of the MSMEG_0317 depletion strains after 18, 24, 27, 30, and 33 hr with or without ATC. After lipid extraction using chloroform/methanol, LM and LAM were extracted from the delipidated pellet by incubation with phenol/water (1:1) for 2 hr at 55°C. Phospholipids and PIMs extracted by chloroform/methanol were further purified by n-butanol/water phase partitioning, and separated by HPTLC (Silica gel 60, EMD Merck) using chloroform/methanol/13 M ammonia/1 M ammonium acetate/water (180:140:9:9:23). Phospholipids were visualized via cupric acetate staining. PIMs were visualized with orcinol staining as described (Sena et al., 2010). LM/LAM samples were separated by SDS-PAGE (15% gel) and visualized using ProQ Emerald 488 glycan staining kit (Life Technologies). To detect LM/LAM in culture supernatants, the supernatants were initially treated with a final concentration of 50 μg/ml Proteinase K for 4 hr at 50°C. The treated supernatants were electrophoresed on 15% SDS-PAGE. LM/LAM were blotted onto nitrocellulose at 20 V for 45 min using semi-dry transfer method. Post transfer, the membrane was blocked by 5% milk in Tris-buffered saline supplemented with 0.05% Tween-20 (TBST). The blocked membrane was then probed overnight with CS-35 antibody (BEI Resources, NIH) at 1:250 dilution at 4°C. The membrane was washed with TBST five times for 5 min each. Post washing, it was probed with anti-mouse secondary for 1 hr at room temperature. Membrane was then washed five times for 5 min with TBST. Thermo Scientific’s west dura chemiluminescent reagent was used to develop the membrane.

Sample preparation and image collection for cryo-EM

Wild type and MSMEG_0317 depleted M. smegmatis cells were pelleted, washed twice with 1× PBS, and suspended in ~20 µl PBS. The culture was subsequently deposited onto freshly glow-discharged holey carbon grids. The grids were then blotted with filter paper manually for about 4 s and rapidly frozen in liquid ethane. The frozen grids were transferred into a 300 kV Titan Krios electron microscope (Thermo Fisher Scientific) equipped with a K2 Summit direct detector and a quantum energy filter (Gatan, Pleasanton, CA). Cryo-EM movie stacks were collected using SerialEM (Mastronarde, 2005). MotionCor2 (Zheng et al., 2017) was used for drift correction of the cryo-EM movie stacks. The gray levels of each micrograph are obtained using MATLAB.

Experimental replicates

Biological replicates are defined as independent cultures grown in parallel or on separate days. Technical replicates are defined at the same culture, measured independently. All the experiments were performed at least twice – often three or more times – with biological replicates.

Acknowledgements

We thank members of the Rego lab for helpful suggestions. This work was supported by the National Institutes of Health, R01AI148255 to EHR, who was also supported by the Searle and Pew Foundations. BMS was supported by the National Science Foundation (CAREER Award 1654408). CW and JL were supported by the NIH grants R01AI087946 and R01GM110243.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

E Hesper Rego, Email: hesper.rego@yale.edu.

Christina L Stallings, Washington University School of Medicine, United States.

Suzanne R Pfeffer, Stanford University, United States.

Funding Information

This paper was supported by the following grants:

  • National Institute of Allergy and Infectious Diseases R01AI148255 to E Hesper Rego.

  • National Science Foundation 1654408 to Benjamin M Swarts.

  • National Institute of Allergy and Infectious Diseases R01AI087946 to Jun Liu.

  • National Institute of General Medical Sciences R01GM110243 to Jun Liu.

  • Pew Charitable Trusts to E Hesper Rego.

  • Searle Scholars Program to E Hesper Rego.

Additional information

Competing interests

No competing interests declared.

Author contributions

Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Conceptualization, Data curation, Formal analysis, Investigation, Writing - review and editing.

Resources, Formal analysis, Investigation, Writing - review and editing.

Resources, Formal analysis, Investigation, Methodology, Writing - review and editing.

Resources, Formal analysis, Investigation, Writing - review and editing.

Investigation, Writing - review and editing.

Resources, Formal analysis, Supervision, Funding acquisition, Writing - review and editing.

Resources, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing.

Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Writing - review and editing.

Additional files

Supplementary file 1. A list of primers and oligos used in this study.
elife-80395-supp1.xlsx (12.6KB, xlsx)
MDAR checklist

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. Source Data files have been provided for blots, gels and TLC figures, and the Tn-seq data shown in Figure 4.

References

  1. Abdali N, Younas F, Mafakheri S, Pothula KR, Kleinekathöfer U, Tauch A, Benz R. Identification and characterization of smallest pore-forming protein in the cell wall of pathogenic corynebacterium urealyticum DSM 7109. BMC Biochemistry. 2018;19:3. doi: 10.1186/s12858-018-0093-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adams O, Deme JC, Parker JL, Fowler PW, Lea SM, Newstead S, CRyPTIC Consortium Cryo-em structure and resistance landscape of M. tuberculosis mmpl3: an emergent therapeutic target. Structure. 2021;29:1182–1191. doi: 10.1016/j.str.2021.06.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, Fortune SM. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science. 2012;335:100–104. doi: 10.1126/science.1216166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Backus KM, Dolan MA, Barry CS, Joe M, McPhie P, Boshoff HIM, Lowary TL, Davis BG, Barry CE. The three Mycobacterium tuberculosis antigen 85 isoforms have unique substrates and activities determined by non-active site regions. The Journal of Biological Chemistry. 2014;289:25041–25053. doi: 10.1074/jbc.M114.581579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baranowski C, Rego EH, Rubin EJ. The dream of a mycobacterium. Microbiology Spectrum. 2019;7:GPP3-0008-2018. doi: 10.1128/microbiolspec.GPP3-0008-2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Belardinelli JM, Stevens CM, Li W, Tan YZ, Jones V, Mancia F, Zgurskaya HI, Jackson M. The mmpl3 interactome reveals a complex crosstalk between cell envelope biosynthesis and cell elongation and division in mycobacteria. Scientific Reports. 2019;9:e10728-8. doi: 10.1038/s41598-019-47159-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bhamidi S, Scherman MS, Rithner CD, Prenni JE, Chatterjee D, Khoo KH, McNeil MR. The identification and location of succinyl residues and the characterization of the interior arabinan region allow for a model of the complete primary structure of Mycobacterium tuberculosis mycolyl arabinogalactan. The Journal of Biological Chemistry. 2008;283:12992–13000. doi: 10.1074/jbc.M800222200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB, Li S, Ehrt S, Chait BT, Schnappinger D, Rock JM. Genome-Wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell. 2021;184:4579–4592. doi: 10.1016/j.cell.2021.06.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cashmore TJ, Klatt S, Yamaryo-Botte Y, Brammananth R, Rainczuk AK, McConville MJ, Crellin PK, Coppel RL. Identification of a membrane protein required for lipomannan maturation and lipoarabinomannan synthesis in Corynebacterineae. The Journal of Biological Chemistry. 2017;292:4976–4986. doi: 10.1074/jbc.M116.772202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chiaradia L, Lefebvre C, Parra J, Marcoux J, Burlet-Schiltz O, Etienne G, Tropis M, Daffé M. Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Scientific Reports. 2017;7:12807–12812. doi: 10.1038/s41598-017-12718-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Degiacomi G, Benjak A, Madacki J, Boldrin F, Provvedi R, Palù G, Kordulakova J, Cole ST, Manganelli R. Essentiality of MmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression. Scientific Reports. 2017;7:43495. doi: 10.1038/srep43495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. DeJesus MA, Ambadipudi C, Baker R, Sassetti C, Ioerger TR. TRANSIT--a software tool for himar1 tnseq analysis. PLOS Computational Biology. 2015;11:e1004401. doi: 10.1371/journal.pcbi.1004401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE, Boutte CC, Rubin EJ, Schnappinger D, Ehrt S, Fortune SM, Sassetti CM, Ioerger TR. Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. MBio. 2017;8:e02133-16. doi: 10.1128/mBio.02133-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dragset MS, Ioerger TR, Zhang YJ, Mærk M, Ginbot Z, Sacchettini JC, Flo TH, Rubin EJ, Steigedal M. Genome-wide phenotypic profiling identifies and categorizes genes required for mycobacterial low iron fitness. Scientific Reports. 2019;9:11394. doi: 10.1038/s41598-019-47905-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fay A, Czudnochowski N, Rock JM, Johnson JR, Krogan NJ, Rosenberg O, Glickman MS. Two accessory proteins govern mmpl3 mycolic acid transport in mycobacteria. MBio. 2019;10:e00850-19. doi: 10.1128/mBio.00850-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fenton AK, Manuse S, Flores-Kim J, Garcia PS, Mercy C, Grangeasse C, Bernhardt TG, Rudner DZ. Phosphorylation-dependent activation of the cell wall synthase pbp2a in streptococcus pneumoniae by macp. PNAS. 2018;115:2812–2817. doi: 10.1073/pnas.1715218115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. García-Heredia A, Pohane AA, Melzer ES, Carr CR, Fiolek TJ, Rundell SR, Lim HC, Wagner JC, Morita YS, Swarts BM, Siegrist MS. Peptidoglycan precursor synthesis along the sidewall of pole-growing mycobacteria. eLife. 2018;7:e37243. doi: 10.7554/eLife.37243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hoffmann C, Leis A, Niederweis M, Plitzko JM, Engelhardt H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. PNAS. 2008;105:3963–3967. doi: 10.1073/pnas.0709530105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jackson M. The mycobacterial cell envelope-lipids. Cold Spring Harbor Perspectives in Medicine. 2014;4:a021105. doi: 10.1101/cshperspect.a021105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jankute M, Cox JAG, Harrison J, Besra GS. Assembly of the mycobacterial cell wall. Annual Review of Microbiology. 2015;69:405–423. doi: 10.1146/annurev-micro-091014-104121. [DOI] [PubMed] [Google Scholar]
  21. Kavunja HW, Biegas KJ, Banahene N, Stewart JA, Piligian BF, Groenevelt JM, Sein CE, Morita YS, Niederweis M, Siegrist MS, Swarts BM. Photoactivatable glycolipid probes for identifying mycolate-protein interactions in live mycobacteria. Journal of the American Chemical Society. 2020;142:7725–7731. doi: 10.1021/jacs.0c01065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kieser KJ, Rubin EJ. How sisters grow apart: mycobacterial growth and division. Nature Reviews. Microbiology. 2014;12:550–562. doi: 10.1038/nrmicro3299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kilburn JO, Takayama K. Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in Mycobacterium smegmatis. Antimicrobial Agents and Chemotherapy. 1981;20:401–404. doi: 10.1128/AAC.20.3.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, Botta M, De Logu A, Rubin EJ, De Rossi E. Mmpl3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrobial Agents and Chemotherapy. 2012;56:324–331. doi: 10.1128/AAC.05270-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lewis JA, Hatfull GF. Identification and characterization of mycobacteriophage L5 excisionase. Molecular Microbiology. 2000;35:350–360. doi: 10.1046/j.1365-2958.2000.01695.x. [DOI] [PubMed] [Google Scholar]
  26. Martini MC, Zhou Y, Sun H, Shell SS. Defining the transcriptional and post-transcriptional landscapes of Mycobacterium smegmatis in aerobic growth and hypoxia. Frontiers in Microbiology. 2019;10:36–51. doi: 10.3389/fmicb.2019.00591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mastronarde DN. Automated electron microscope tomography using robust prediction of specimen movements. Journal of Structural Biology. 2005;152:36–51. doi: 10.1016/j.jsb.2005.07.007. [DOI] [PubMed] [Google Scholar]
  28. Mikusová K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrobial Agents and Chemotherapy. 1995;39:2484–2489. doi: 10.1128/AAC.39.11.2484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Palčeková Z, Angala SK, Belardinelli JM, Eskandarian HA, Joe M, Brunton R, Rithner C, Jones V, Nigou J, Lowary TL, Gilleron M, McNeil M, Jackson M. Disruption of the suct acyltransferase in Mycobacterium smegmatis abrogates succinylation of cell envelope polysaccharides. The Journal of Biological Chemistry. 2019;294:10325–10335. doi: 10.1074/jbc.RA119.008585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Paradis-Bleau C, Markovski M, Uehara T, Lupoli TJ, Walker S, Kahne DE, Bernhardt TG. Lipoprotein cofactors located in the outer membrane activate bacterial cell wall polymerases. Cell. 2010;143:1110–1120. doi: 10.1016/j.cell.2010.11.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pashley CA, Parish T. Efficient switching of mycobacteriophage L5-based integrating plasmids in Mycobacterium tuberculosis. FEMS Microbiology Letters. 2003;229:211–215. doi: 10.1016/S0378-1097(03)00823-1. [DOI] [PubMed] [Google Scholar]
  32. Patel O, Brammananth R, Dai W, Panjikar S, Coppel RL, Lucet IS, Crellin PK. Crystal structure of the putative cell-wall lipoglycan biosynthesis protein lmca from Mycobacterium smegmatis. Acta Crystallographica. Section D, Structural Biology. 2022;78:494–508. doi: 10.1107/S2059798322001772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rahlwes KC, Puffal J, Morita YS. In: In Bacterial Polysaccharides: Methods and Protocols, Brockhausen, Inka. Rahlwes KC, editor. New York, NY: Springer; 2019. Purification and analysis of mycobacterial phosphatidylinositol mannosides, lipomannan, and lipoarabinomannan; pp. 59–75. [DOI] [PubMed] [Google Scholar]
  34. Rego EH, Audette RE, Rubin EJ. Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity. Nature. 2017;546:153–157. doi: 10.1038/nature22361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rock JM, Hopkins FF, Chavez A, Diallo M, Chase MR, Gerrick ER, Pritchard JR, Church GM, Rubin EJ, Sassetti CM, Schnappinger D, Fortune SM. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nature Microbiology. 2017;2:16274. doi: 10.1038/nmicrobiol.2016.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sena CBC, Fukuda T, Miyanagi K, Matsumoto S, Kobayashi K, Murakami Y, Maeda Y, Kinoshita T, Morita YS. Controlled expression of branch-forming mannosyltransferase is critical for mycobacterial lipoarabinomannan biosynthesis. The Journal of Biological Chemistry. 2010;285:13326–13336. doi: 10.1074/jbc.M109.077297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Soltan Mohammadi N, Mafakheri S, Abdali N, Bárcena-Uribarri I, Tauch A, Benz R. Identification and characterization of the channel-forming protein in the cell wall of corynebacterium amycolatum. Biochimica et Biophysica Acta. 2013;1828:2574–2582. doi: 10.1016/j.bbamem.2013.06.024. [DOI] [PubMed] [Google Scholar]
  38. Su CC, Klenotic PA, Bolla JR, Purdy GE, Robinson CV, Yu EW. MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine. PNAS. 2019;116:11241–11246. doi: 10.1073/pnas.1901346116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Su CC, Klenotic PA, Cui M, Lyu M, Morgan CE, Yu EW. Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport. PLOS Biology. 2021;19:e3001370. doi: 10.1371/journal.pbio.3001370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, Boshoff HI. Sq109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2012;56:1797–1809. doi: 10.1128/AAC.05708-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Typas A, Banzhaf M, van den Berg van Saparoea B, Verheul J, Biboy J, Nichols RJ, Zietek M, Beilharz K, Kannenberg K, von Rechenberg M, Breukink E, den Blaauwen T, Gross CA, Vollmer W. Regulation of peptidoglycan synthesis by outer-membrane proteins. Cell. 2010;143:1097–1109. doi: 10.1016/j.cell.2010.11.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Umare MD, Khedekar PB, Chikhale RV. Mycobacterial membrane protein large 3 (MmpL3) inhibitors: a promising approach to combat tuberculosis. ChemMedChem. 2021;16:3136–3148. doi: 10.1002/cmdc.202100359. [DOI] [PubMed] [Google Scholar]
  43. van Kessel JC, Hatfull GF. Recombineering in Mycobacterium tuberculosis. Nature Methods. 2007;4:147–152. doi: 10.1038/nmeth996. [DOI] [PubMed] [Google Scholar]
  44. Wu KJ, Zhang J, Baranowski C, Leung V, Rego EH, Morita YS, Rubin EJ, Boutte CC. Characterization of conserved and novel septal factors in mycobacterium smegmatis. Journal of Bacteriology. 2018;200:e00649-17. doi: 10.1128/JB.00649-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wuo MG, Dulberger CL, Brown RA, Sturm A, Ultee E, Bloom-Ackermann Z, Choi C, Garner EC, Briegel A, Hung DT, Rubin EJ, Kiessling LL. Antibiotic Action Revealed by Real-Time Imaging of the Mycobacterial Membrane. bioRxiv. 2022 doi: 10.1101/2022.01.07.475452. [DOI]
  46. Xu Z, Meshcheryakov VA, Poce G, Chng SS. Mmpl3 is the flippase for mycolic acids in mycobacteria. PNAS. 2017;114:7993–7998. doi: 10.1073/pnas.1700062114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Zhang YJ, Ioerger TR, Huttenhower C, Long JE, Sassetti CM, Sacchettini JC, Rubin EJ. Global assessment of genomic regions required for growth in mycobacterium tuberculosis. PLOS Pathogens. 2012;8:e1002946. doi: 10.1371/journal.ppat.1002946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Zheng SQ, Palovcak E, Armache J-P, Verba KA, Cheng Y, Agard DA. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nature Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffé M. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. Journal of Bacteriology. 2008;190:5672–5680. doi: 10.1128/JB.01919-07. [DOI] [PMC free article] [PubMed] [Google Scholar]

Editor's evaluation

Christina L Stallings 1

This manuscript tackles the important and fundamental question of what proteins regulate asymmetrical cell division in Mycobacteria. This strong study will be of interest to all individuals interested in bacterial physiology and the conclusions are well-supported by the data.

Decision letter

Editor: Christina L Stallings1

Our editorial process produces two outputs: i) public reviews designed to be posted alongside the preprint for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article, "An essential periplasmic protein coordinates lipid trafficking and is required for asymmetric polar growth in mycobacteria" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Suzanne Pfeffer as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

Please see the specific comments from the reviewers below. To summarize:

1) The TLC data are qualitative and difficult to assess significance. Quantitative data from several experiments should be included.

2) The conclusions for whether LmcA and PgfA are (or are not) orthologs are not strongly supported and should be revisited.

3) Overall, please re-assess the specific conclusions of the manuscript and either provide data to support the conclusions or temper claims. Details follow below.

Reviewer #1 (Recommendations for the authors):

– Conclusions in Lines 100-101: The inability of LmcA to substitute for PgfA does not mean these proteins are not orthologs, there are many other factors that contribute to heterologous complementation, including the similarity of other binding partners or chaperones. The data that may support the proteins are not orthologs is the absence of an effect on LAM in the PgfA depletion mutant. However, the overexpression of PgfA does lead to changes in LAM. So both proteins still have connections to these pathways and it is not convincing that the proteins are not orthologs performing functions specific to the physiology of the different bacteria.

– In lines 113-116, the authors reference the data in Figure 1B as being the differences in colonies that grew while performing the allele swapping strategy with the empty vector. Did the colonies that grew actually exhibit a loss of PfgA? Or did these isolates still contain the WT gene? It seems important to understand this in order to make conclusions about essentiality.

– Conclusions in Lines 150-152– how do the experiments with the RFP tagged PgfA show that PgfA is required for polar growth? The experiments in 1C support that PgfA is involved in cell elongation, but most strikingly it appears to be involved through the envelope integrity. But the polarity of growth is never measured during PgfA depletion. Then the experiments with the RFP tagged PgfA only show localization, but do not test what processes PgfA is required for. In this regard, line 347 is also not supported by the data it references. The authors never actually show that the pgfA mutant is deficient in polar growth.

– The authors first mention in line 199 that pgfA is in an operon. Did the authors check if there were polar effects in the mutant used in Figures 1 and 2A? For the experiments in Figure 2D, was the expression of MSMEG_0315 at WT levels at the heterologous site? What is MSMEG_0315? Is there a conserved homolog in Mtb?

– For lines 215-216, the authors claim their data suggest that cells depleted for PgfA accumulate TMM, but this is not shown, much less whether it accumulates to toxic levels. Later in the manuscript, the authors perform the TLCs, so this conclusion should follow the experimental data to support it. In addition, some of the differences in the TLCs are rather small. Replicate TLCs could be quantified, graphed, and stats performed to determine the rigor of the data.

– Do the authors have an interpretation of why TMM also increases in the overexpression strain in Figure 3D, and how does this fit into their model?

– Lines 259-260 – it could be more direct to reword the sentence so that it is clear that it is unknown what region of PgfA binds the TMM analog.

– Is there a reason that in the section starting on line 281, the authors call the corynebacterial homolog NCgI2760 instead of LmcA? Are these the same protein?

Reviewer #2 (Recommendations for the authors):

1. The TLC data in Figures 3C and D are qualitative and difficult to assess significance. Quantitative data on the relative abundance of the TDM and TMM bands from several experiments should be included.

2. The Results section entitled "The function of PgfA is specific to mycobacteria and its abundance negatively correlates with the abundance of lipoglycans LM/LAM" is quite long and spends a lot of time discussing data indicating that PgfA is not an ortholog of NCgl2760 from C. glutamicum. While this is useful information, it detracts from the main thrust of the manuscript-the contribution of PgfA to asymmetric growth. I recommend revising this section to reduce its length and increase focus.

Reviewer #3 (Recommendations for the authors):

1) The authors propose that PgfA is involved in the traffic of mycolic acids in the periplasmic space. I think the data support this idea. However, I think it would strengthen the paper to discuss in more detail what steps in the trafficking process remain unknown and where PgfA might fit into it. For example, is it potentially involved in extracting TMM from the membrane and handing it off to Ag85 proteins for transport? Are there other possibilities? More specific context such as this would improve the Discussion section and make it more impactful.

2) I am not convinced that the depletion of PgfA appreciably changes the levels of TMM or TDM in cells. Firstly, it would be helpful to know how the authors assigned the TLC spots to TMM and TDM? Controls would be helpful here, such as the inhibition of TMM synthesis to show which spots disappear. Also, in addition to adding better controls to assign the spots, some quantitation is needed. I don't see much in the way of changes to the TMM and TDM spots by eye when PgfA is depleted. In addition, there are new spots appearing at the top of the TLC plate in the PgfA-depleted cells. What species are these? Their identification could shed more light on PgfA function as they are unique to PgfA depletion and not observed in the MmpL3 depletion. At a minimum, this observation should be highlighted in the text given how striking it is (much more striking than the TMM/TDM changes).

3) The topology experiments are not especially convincing. The reduced fluorescence of the N-terminal fusion makes it hard to draw strong conclusions from this construct. Is there a small amount of protein with GFP inside that is non-functional combined with a larger fraction of non-fluorescent protein with GFP outside that accounts for the functionality of the construct? I think it is probably sufficient to rely on the topology prediction supported by the C-in result from the C-terminal GFP fusion. These combine to make a reasonable case for the proposed topology as long as the caveat is made that further experiments are needed to definitively establish the topology.

4) As mentioned above, I do not find the argument that NCgl2760 has a different function than PgfA to be convincing. This section should be (significantly) revised to account for the much more reasonable conclusion that cross complementation does not work simply because of divergent protein-protein interactions and/or mycolic acid length between organisms. The fact that PgfA/ NCgl2760 has differential effects on LM/LAM accumulation in their respective host organisms could simply be due to differential stress/regulatory responses downstream of the same primary defect.

5) The overexpression studies in Figure 5 have several problems. Firstly, were the results normalized for growth rate changes? It seems like the growth rate could significantly affect the outcome of the experiment and the relative elongation at the different poles observed. Secondly, it is concluded that PfgA overproduction but not MmpL3 overproduction restores asymmetric growth to δ-lamA cells. The results for these two strains don't look all that different to me. Some statistics are needed here.

6) Line 389: "regulating" is misused here and in other sections of the paper. Just because the inactivation of PgfA causes a change in envelope structure/composition does not mean it is a regulator. The regulator designation implies that it is responsive to stimuli, but there is no data supporting this designation. It seems more likely to me that PgfA is a core component of the transport apparatus and that its inactivation alters the envelope because the normal process is disrupted, not because it is a regulator.

7) Lines 402-415: I think some speculation is important to include in a Discussion section. However, the connection for PgfA with peptidoglycan synthesis is a bit too much of a leap for this paper. I would remove this paragraph.

8) Line 418-420: Rather than different growth requirements at the two poles, couldn't the results be interpreted as a competition between the two poles for common precursors/protein components? A competition model involving some positive feedback at the favored pole seems simpler and therefore more likely.

9) Line 215-219: Reference to TMM accumulation is made, but this comes well before the TMM levels are quantified later in the paper and the figure is not referenced. Some rewriting is needed to improve the flow of the paper here. Also, as mentioned above, I do not think the data showing TMM accumulation is convincing as presented.

10) Figure 2B: Please show the blots for the input material as well as the blots for anti-GFP as well as anti-FLAG blots.

11) Figure 2C: Make the font bigger for PgfA and MmpL3 or find some other way to make the labels clearer.

eLife. 2022 Nov 8;11:e80395. doi: 10.7554/eLife.80395.sa2

Author response


Essential revisions:

Please see the specific comments from the reviewers below. To summarize:

1) The TLC data are qualitative and difficult to assess significance. Quantitative data from several experiments should be included.

2) The conclusions for whether LmcA and PgfA are (or are not) orthologs are not strongly supported and should be revisited.

3) Overall, please re-assess the specific conclusions of the manuscript and either provide data to support the conclusions or temper claims. Details follow below.

We thank the reviewers for their time and thoughtful commentary. To address their concerns, we have quantified the TLC data, and determined statistical significance. These data support our conclusions and can be found in Figure 3E-F. We have also revised the text to de-emphasize our studies and interpretations around LmcA and PgfA complementation.

Reviewer #1 (Recommendations for the authors):

– Conclusions in Lines 100-101: The inability of LmcA to substitute for PgfA does not mean these proteins are not orthologs, there are many other factors that contribute to heterologous complementation, including the similarity of other binding partners or chaperones. The data that may support the proteins are not orthologs is the absence of an effect on LAM in the PgfA depletion mutant. However, the overexpression of PgfA does lead to changes in LAM. So both proteins still have connections to these pathways and it is not convincing that the proteins are not orthologs performing functions specific to the physiology of the different bacteria.

In response to comments from all authors, we have we-written this section and de-emphasized the notion that PgfA and LmcA are not orthologs. Please see lines 313-335.

– In lines 113-116, the authors reference the data in Figure 1B as being the differences in colonies that grew while performing the allele swapping strategy with the empty vector. Did the colonies that grew actually exhibit a loss of PfgA? Or did these isolates still contain the WT gene? It seems important to understand this in order to make conclusions about essentiality.

The few colonies that grew when exchanged for an empty vector control were verified to be double integrants, meaning that they contain a copy of pgfA as well as the vector control at the L5 site. We think that these data, in addition to the data found in Figure 1C and Figure 1 —figure supplement 1A,B, make a strong case for pgfA being an essential gene.

– Conclusions in Lines 150-152– how do the experiments with the RFP tagged PgfA show that PgfA is required for polar growth? The experiments in 1C support that PgfA is involved in cell elongation, but most strikingly it appears to be involved through the envelope integrity. But the polarity of growth is never measured during PgfA depletion. Then the experiments with the RFP tagged PgfA only show localization, but do not test what processes PgfA is required for. In this regard, line 347 is also not supported by the data it references. The authors never actually show that the pgfA mutant is deficient in polar growth.

To verify that PgfA and MmpL3 are important for polar growth, we have performed a new experiment to visualize the amount of new growth added at the poles in cells depleted for these proteins. These data can be found in Figure 1 —figure supplement 2, and in text on lines 128-132 and 218.

– The authors first mention in line 199 that pgfA is in an operon. Did the authors check if there were polar effects in the mutant used in Figures 1 and 2A? For the experiments in Figure 2D, was the expression of MSMEG_0315 at WT levels at the heterologous site? What is MSMEG_0315? Is there a conserved homolog in Mtb?

MSMEG_0315 is predicted to be a transmembrane protein of unknown function that is conserved in Mtb, Rv0226c. Tn-seq and CRISPRi studies predict these genes to be essential. There have not been any studies on this protein in mycobacteria. However, there is one report where it is shown to be involved in the transport of cornomycolates in C. glutamicum (Cashmore et al. Biomolecules 2021).

The mutant used in Figures 1 and 2A was generated by an in-frame deletion of msmeg_0317. As we were able to make this mutant, in a background with only pgfA at phage site, we inferred that this did not interrupt the expression of the second gene of the operon, msmeg_0315, as it is predicted to be essential. Additionally, the ATC-inducible pgfA was at a phage site, uncoupling it from the expression of msmeg_0315, and so we feel confident that the phenotypes we report are due to changes in MSMEG_0317 (PgfA) levels. However, we were concerned about the known polar effects of CRISPRi, and we have verified that MSMEG_0315 is being expressed in this strain background by Western blot Figure 2 —figure supplement 4.

– For lines 215-216, the authors claim their data suggest that cells depleted for PgfA accumulate TMM, but this is not shown, much less whether it accumulates to toxic levels. Later in the manuscript, the authors perform the TLCs, so this conclusion should follow the experimental data to support it. In addition, some of the differences in the TLCs are rather small. Replicate TLCs could be quantified, graphed, and stats performed to determine the rigor of the data.

We have removed the conclusion of line 215-216 in the revised manuscript and put it in the appropriate section. See Figure 3E-F for quantification of TLC.

– Do the authors have an interpretation of why TMM also increases in the overexpression strain in Figure 3D, and how does this fit into their model?

We agree that there appears to be a small increase in TMM in the PgfA overexpression, but this difference is not statistically significant across replicates (Figure 3E-F).

– Lines 259-260 – it could be more direct to reword the sentence so that it is clear that it is unknown what region of PgfA binds the TMM analog.

Reworded on lines 270.

– Is there a reason that in the section starting on line 281, the authors call the corynebacterial homolog NCgI2760 instead of LmcA? Are these the same protein?

We have updated the manuscript to refer to NCgl2760 as LmcA throughout to avoid confusion.

Reviewer #2 (Recommendations for the authors):

1. The TLC data in Figures 3C and D are qualitative and difficult to assess significance. Quantitative data on the relative abundance of the TDM and TMM bands from several experiments should be included.

See above.

2. The Results section entitled "The function of PgfA is specific to mycobacteria and its abundance negatively correlates with the abundance of lipoglycans LM/LAM" is quite long and spends a lot of time discussing data indicating that PgfA is not an ortholog of NCgl2760 from C. glutamicum. While this is useful information, it detracts from the main thrust of the manuscript-the contribution of PgfA to asymmetric growth. I recommend revising this section to reduce its length and increase focus.

We thank the reviewer for this insightful comment that will improve the flow and comprehensibility of our manuscript to the reader. The text has been edited to increase clarity and de-emphasize this section.

Reviewer #3 (Recommendations for the authors):

1) The authors propose that PgfA is involved in the traffic of mycolic acids in the periplasmic space. I think the data support this idea. However, I think it would strengthen the paper to discuss in more detail what steps in the trafficking process remain unknown and where PgfA might fit into it. For example, is it potentially involved in extracting TMM from the membrane and handing it off to Ag85 proteins for transport? Are there other possibilities? More specific context such as this would improve the Discussion section and make it more impactful.

We thank the reviewer for this suggestion. We have reorganized the discussion and have included a paragraph (lines 427-436) in the discussion on this important topic.

2) I am not convinced that the depletion of PgfA appreciably changes the levels of TMM or TDM in cells. Firstly, it would be helpful to know how the authors assigned the TLC spots to TMM and TDM? Controls would be helpful here, such as the inhibition of TMM synthesis to show which spots disappear. Also, in addition to adding better controls to assign the spots, some quantitation is needed. I don't see much in the way of changes to the TMM and TDM spots by eye when PgfA is depleted. In addition, there are new spots appearing at the top of the TLC plate in the PgfA-depleted cells. What species are these? Their identification could shed more light on PgfA function as they are unique to PgfA depletion and not observed in the MmpL3 depletion. At a minimum, this observation should be highlighted in the text given how striking it is (much more striking than the TMM/TDM changes).

We agree that this is an important point. TMM and TDM spots were assigned by several methods. First, TLCs were performed using established protocols to get a general sense of how the lipids migrated. Secondly, we depleted or deleted genes known to affect TMM and TDM levels. We show MmpL3 depleted cells in the main text, but now include TLC data from an antigen-85a KO, as well. Lastly, as the reviewer suggested, we treated cells with isoniazid to inhibit TMM synthesis and see the spots corresponding to TMM and TDM decrease. These data can be found in Figure 3 —figure supplement 3. Together, these controls were used to appropriately assign spots on the TLCs. Of note, we also obtained purified TMM and TDM controls from Mycobacterium tuberculosis (ATCC NR-48784 and NR-14844) to use as controls. However, species differences meant that these lipids exhibit significant differences in migration patterns and therefore were not appropriate controls for our experiments.

The new spots appearing on the top of TLC plates in PgfA-depleted cells are glycopeptidolipids (GPLs). These outer membrane lipids are responsible colony morphology, biofilm formation and sliding motility of Msm and other NTM species. We think that the mycomembrane disruption caused due to PgfA depletion might contribute to better extraction of GPLs from the depleted cells. However, we have not observed consistent patterns of these bands across replicates in the different genetic backgrounds, and do not feel comfortable drawing conclusions about their significance.

3) The topology experiments are not especially convincing. The reduced fluorescence of the N-terminal fusion makes it hard to draw strong conclusions from this construct. Is there a small amount of protein with GFP inside that is non-functional combined with a larger fraction of non-fluorescent protein with GFP outside that accounts for the functionality of the construct? I think it is probably sufficient to rely on the topology prediction supported by the C-in result from the C-terminal GFP fusion. These combine to make a reasonable case for the proposed topology as long as the caveat is made that further experiments are needed to definitively establish the topology.

We have revised this section (lines 261-266).

4) As mentioned above, I do not find the argument that NCgl2760 has a different function than PgfA to be convincing. This section should be (significantly) revised to account for the much more reasonable conclusion that cross complementation does not work simply because of divergent protein-protein interactions and/or mycolic acid length between organisms. The fact that PgfA/ NCgl2760 has differential effects on LM/LAM accumulation in their respective host organisms could simply be due to differential stress/regulatory responses downstream of the same primary defect.

We agree and have re-written this section to deemphasize the complementation studies.

5) The overexpression studies in Figure 5 have several problems. Firstly, were the results normalized for growth rate changes? It seems like the growth rate could significantly affect the outcome of the experiment and the relative elongation at the different poles observed. Secondly, it is concluded that PfgA overproduction but not MmpL3 overproduction restores asymmetric growth to δ-lamA cells. The results for these two strains don't look all that different to me. Some statistics are needed here.

As demonstrated in Figure 5 —figure supplement 1, there is no difference in growth rate between the strains used in Figure 5A. We now show replicate data in Figure 5A. We determined statistical significance by comparing the averages of the replicate single-cell distributions (aka a “super plot”). This much more rigorous analysis confirms our original conclusion that increased expression of PgfA restores growth at the old pole in ΔlamA cells.

6) Line 389: "regulating" is misused here and in other sections of the paper. Just because the inactivation of PgfA causes a change in envelope structure/composition does not mean it is a regulator. The regulator designation implies that it is responsive to stimuli, but there is no data supporting this designation. It seems more likely to me that PgfA is a core component of the transport apparatus and that its inactivation alters the envelope because the normal process is disrupted, not because it is a regulator.

We agree and have made the appropriate changes to remove “regulating” from the manuscript in reference to PgfA.

7) Lines 402-415: I think some speculation is important to include in a Discussion section. However, the connection for PgfA with peptidoglycan synthesis is a bit too much of a leap for this paper. I would remove this paragraph.

We have softened some of the language in this section as to not over-reach the conclusions of our data. However, we believe that this is an interesting avenue of research given the trend of peptidoglycan synthesis activation by lipoproteins in other bacterial species. It follows that the pathways that govern lipid trafficking may be involved in similar regulatory mechanisms in mycobacteria.

8) Line 418-420: Rather than different growth requirements at the two poles, couldn't the results be interpreted as a competition between the two poles for common precursors/protein components? A competition model involving some positive feedback at the favored pole seems simpler and therefore more likely.

We have considered the hypothesis that the two poles are competing for common precursors; however, we think that our results do not support this model. In a precursor competition model, it would be expected that when there is a decreased demand for precursors at the favorable pole, the rate of elongation would increase at the un-favored pole. In fact, we see in Figure 5A that, in different genetic backgrounds, growth can increase at one side of the side without compensatory decreases in growth on the other side (ΔlamA+ pgfA), and vice versa (ΔlamA+ mmpL3).

9) Line 215-219: Reference to TMM accumulation is made, but this comes well before the TMM levels are quantified later in the paper and the figure is not referenced. Some rewriting is needed to improve the flow of the paper here. Also, as mentioned above, I do not think the data showing TMM accumulation is convincing as presented.

See above.

10) Figure 2B: Please show the blots for the input material as well as the blots for anti-GFP as well as anti-FLAG blots.

Now included as Figure 2 —figure supplement 2.

11) Figure 2C: Make the font bigger for PgfA and MmpL3 or find some other way to make the labels clearer.

Labels for this figure have been made clearer.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Figure 2—source data 1. Unprocessed anti-FLAG Western blot.
    Figure 2—source data 2. Unprocessed and labeled anti-FLAG Western blot.
    Figure 2—figure supplement 2—source data 1. Unprocessed anti-FLAG Western blot.
    Figure 2—figure supplement 2—source data 2. Unprocessed and labeled anti-FLAG Western blot.
    Figure 2—figure supplement 2—source data 3. Unprocessed and labeled anti-GFP Western blot.
    Figure 2—figure supplement 2—source data 4. Unprocessed and labeled anti-GFP Western blot.
    Figure 2—figure supplement 4—source data 1. Unprocessed anti-strep Western blot.
    Figure 2—figure supplement 4—source data 2. Unprocessed and labeled anti-strep Western blot.
    Figure 3—source data 1. Unprocessed MmpL3 depletion thin-layer chromatography (TLC).
    Figure 3—source data 2. Unprocessed and labeled MmpL3 depletion thin-layer chromatography (TLC).
    Figure 3—source data 3. Unprocessed PgfA depletion thin-layer chromatography (TLC).
    Figure 3—source data 4. Unprocessed and labeled PgfA depletion thin-layer chromatography (TLC).
    Figure 3—source data 5. Unprocessed PgfA overexpression thin-layer chromatography (TLC).
    Figure 3—source data 6. Unprocessed and labeled PgfA overexpression thin-layer chromatography (TLC).
    Figure 3—figure supplement 1—source data 1. Unprocessed Coomassie gel.
    Figure 3—figure supplement 1—source data 2. Unprocessed in-gel fluorescence scan.
    Figure 3—figure supplement 1—source data 3. Unprocessed anti-FLAG Western blot.
    Figure 3—figure supplement 1—source data 4. Full uncropped gels with relevant bands labeled.
    Figure 3—figure supplement 3—source data 1. Unprocessed thin-layer chromatography (TLC) comparing wild type (WT) Msm to Msm Δantigen85A.
    Figure 3—figure supplement 3—source data 2. Unprocessed and labeled thin-layer chromatography (TLC) comparing wild type (WT) Msm to Msm Δantigen85A.
    Figure 3—figure supplement 3—source data 3. Unprocessed thin-layer chromatography (TLC) comparing wild type (WT) Msm +/-isoniazid.
    Figure 3—figure supplement 3—source data 4. Unprocessed thin-layer chromatography (TLC) and labeled comparing wild type (WT) Msm +/-isoniazid.
    Figure 4—source data 1. Unprocessed lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA depletion.
    Figure 4—source data 2. Unprocessed PIM thin-layer chromatography (TLC) during PgfA depletion.
    Figure 4—source data 3. Unprocessed plasma membrane thin-layer chromatography (TLC) during PgfA depletion.
    Figure 4—source data 4. Unprocessed, lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE, PIM, and plasma membrane thin-layer chromatography (TLC) during PgfA depletion, with relevant bands labeled.
    Figure 4—source data 5. Results of Tn-seq experiment comparing insertions in wild type and ΔlamA.
    elife-80395-fig4-data5.xlsx (578.1KB, xlsx)
    Figure 4—source data 6. Unprocessed lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA overexpression.
    Figure 4—source data 7. Unprocessed and labeled lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA overexpression.
    Figure 4—figure supplement 1—source data 1. Unprocessed lipomannan and lipoarabinomannan (LM/LAM) SDS-PAGE during PgfA overexpression.
    Figure 4—figure supplement 1—source data 2. Unprocessed PIM thin-layer chromatography (TLC) during PgfA overexpression, left-hand side.
    Figure 4—figure supplement 1—source data 3. Unprocessed PIM thin-layer chromatography (TLC) during PgfA overexpression, right-hand side.
    Figure 4—figure supplement 1—source data 4. Unprocessed plasma membrane thin-layer chromatography (TLC) during PgfA overexpression, left-hand side.
    Figure 4—figure supplement 1—source data 5. Unprocessed plasma membrane thin-layer chromatography (TLC) during PgfA overexpression, right-hand side.
    Figure 4—figure supplement 1—source data 6. Full uncropped gels with relevant bands labeled.
    Supplementary file 1. A list of primers and oligos used in this study.
    elife-80395-supp1.xlsx (12.6KB, xlsx)
    MDAR checklist

    Data Availability Statement

    All data generated or analyzed during this study are included in the manuscript and supporting files. Source Data files have been provided for blots, gels and TLC figures, and the Tn-seq data shown in Figure 4.


    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES